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Abstract 
Determination of the in vitro and in vivo Oral Drug Delivery Capabilities of 
Complexation Hydrogels. 
Eric D. Perakslis 
Anthony M. Lowman, Ph.D. 
 
 
 
 The promise of oral delivery formulations of therapeutic protein and peptides 
is one of high hopes but also of disappointment as, to date, parenteral administration 
remains the standard of care.  A good example of this is in the case of human insulin 
delivery for diabetes where disease control, reduction of degenerative side effects and 
increased patient compliance could all be gained in the most rapidly growing disease 
in our country.  Hydrogel carrier systems have shown promise as a potential solution 
for this unmet medical need.  In particular a novel pH-sensitive poly[methacrylic 
acid-grafted-poly(ethylene glycol)] hydrogel system has shown promise by displaying 
enhanced insulin delivery in in situ animal models. 
 In this work, a set of detailed in vitro and in vivo experiments were used to 
further qualify the insulin delivery capabilities of this novel system.  The ability of 
the system to protect entrapped insulin in the upper gastrointestinal tract was 
confirmed via dissolution studies and the ability of the polymer system to enhance 
transport across the intetinal epithelium was confirmed using the Caco-2 in vitro 
model of intestinal transport.   Lastly, the absolute oral bioavailability of insulin 
delivered via the hydrogel system was determined in rats and dogs.  The application 
of pharmacokinetic models to the animal data shows the greatest gains on improving 
this delivery system can be made by optimizing the ability of the hydrogel to enhance 
protein transport across the gut wall.
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CHAPTER 1: INTRODUCTION 
 
 
 The interest, demand and market potential for advanced drug delivery for 
hormones, antibodies and other protein drugs has been well documented [1].  Of 
particular interest is the ability to deliver proteins orally.  Ideally, oral protein 
delivery has the potential to increase patient compliance, lower medical costs and 
provide superior pharmacokinetic profiles [2].  The primary barrier to effective oral 
protein delivery is the ability to obtain adequate bioavailability due to drug 
degradation by proteolytic enzymes and poor transport as it passes through the 
gastrointestinal tract. 
 One promising approach to oral protein delivery is the use of hydrogel 
technology, which has been studied extensively over the last 2 decades [3-9].  Of 
particular interest are pH-sensitive complexation hydrogel systems, which have 
demonstrated significant promise in oral delivery, especially in the specific 
application of oral insulin delivery [10-13].  The poly(methacrylic acid-g-ethylene 
glycol) system developed through this work has demonstrated the ability to enhance 
insulin bioavailability in a closed loop in vivo model compared to insulin alone [12]. 
 In an effort to better understand the capabilities of protein delivery systems, 
and of the complexation hydrogel system in particular, quantitative analysis of drug 
absorption, bioavailability, toxicity and the pharmacokinetic and pharmacodynamic 
properties are required. 
 In vitro cell culture models are commonly used in the study of drug absorption 
mechanisms [14].  The Caco-2 model, a human intestinal epithelial cell line, is 
thought to satisfy the need for an oral absorption model that predicts in vivo situations 
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in a fast and efficient manner [15].  These in vitro tools are very amendable to the 
testing of drug candidates in high numbers but the models are fairly idealized and are 
most often used for initial drug transport estimation via membrane permeability 
studies.  To obtain data that comes closest to predicting outcomes in humans, animal 
models of absorption, distribution, metabolism and excretion (ADME) are still 
essential [16]. 
 This research focuses on presenting a detailed in vitro and in vivo analysis of 
the oral drug delivery capabilities of a novel complexation hydrogel system using 
human insulin as the test article and target protein.  This type of analysis is critical in 
assessing the suitability of any drug delivery system for testing in humans.  Hydrogel 
preparations loaded with insulin were evaluated in membrane permeability studies 
using a Caco-2 cell monolayer model to assess the in vitro transport enhancing 
effects.  The pharmacokinetics and absolute bioavailability of this same system was 
then studied in rats and dogs to provide an estimation of key ADME parameters. 
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CHAPTER 2: BACKGROUND 
 
 
2.1 Protein and peptide therapeutics  
 
  Protein and peptide therapeutics can be defined and differentiated from small 
molecule therapeutics in several important ways.  Besides differences in size, i.e. 
molecular weight, and complexity such as proteins with tertiary and quaternary 
structures, the complexities of manufacture, risks of contamination, purification and 
cost of goods are all distinguishing factors.  Conversely, it is more straightforward to 
define small molecule therapeutics and non-peptide molecules that are ‘drug-like’ as 
per the ‘Pfizer Rule of 5’[1].  This model suggests that a molecule is drug-like if it 
has the following properties: molecular weight under 500; fewer that 5 hydrogen 
bond donors; a logP of less than 5 and fewer that 10 hydrogen bond acceptors.   
Important subclasses of protein and peptide therapeutics include human insulins and 
analogues, growth hormone, interferons, monoclonal antibodies, antimicrobial 
peptides, tissue plasminogen activators, fusion proteins and hematopoietic factors [2].  
This chapter will present a comprehensive review of the utility, promise, challenges 
and economics of this important class of medicines. 
 
2.1.1 Unmet medical need and commercial opportunity  
 
 Estimates vary by source but there is consensus that the worldwide market for 
protein and peptide therapeutics will reach $100 billion by 2008 [3, 4].  This is due, in 
part, to the dramatically increasing success rates for developing biotech drugs.  For 
example, the success rates for rDNA therapeutics entering clinical study between 
1990 and 1997 was 35%, which represents a 35% increase over the success rate for 
 6
analogous drugs entering study between 1980 and 1989 [5].  In fact, the success rates 
for the development of biotech drugs exceeds those of small molecules according to 
public information available through the US Food and Drug Administration (FDA). 
 Driving this expanding market is the tremendous volume of unmet medical 
need in serious disease areas such as; arthritis, inflammation and immune disorders, 
central nervous system, diabetes and endocrinology, genetic disorder, hematology, 
infections diseases and oncology [3].  Many feel that the future treatments of many 
diseases in these serious therapeutic disciplines lies mostly with biological medicines.  
The vision is compelling with an example being the promise of cancer treatments 
without cytotoxic drugs.  This vision is further supported by the fact that small 
molecule chemistry is reaching the limitations of diversity and novelty.  Clearly, the 
promise of improved treatment options for serious diseases as well as the continually 
growing business rationale will continue to drive the future development of biological 
medicines. 
 While protein and peptide therapeutics can be classified via several taxonomic 
approaches, the following classes will be described further in this work; antibody 
therapies, vaccines and hormone therapy.  In addition, the specific case of diabetes 
therapy will be detailed. 
 
2.1.2 Antibody therapies 
 
 Monoclonal antibodies (mAbs) are defined as immunoglobulin (Ig) molecules 
that possess the same structure, as opposed to polyclonal antibodies, which are the 
typical immune response to antigenic challenge.  Both types of antibodies target 
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foreign substances and can be used to effect a specific response to an immune-
mediated disease process.  Monoclonal antibodies are produced by the fusion of an 
individual B-lymphocyte with a cancer cell.  The hybrid cell that results retains the 
antibody-producing capability of the B-lymphocyte with the virtual immortality of a 
cancer cell[6].   
The first monoclonal antibody therapy, Murononab –CD3 (a mouse IgG), was 
approved for use in 1986 for acute allograft rejection in transplant patients.  Since 
then, more than 15 other monoclonal antibodies have entered the market for 
treatments from cancer to rheumatoid arthritis.  While these therapies carry their own 
set of side effects and long-term adverse event data does not yet exist, they are 
considered very safe when compared with other therapy options used in diseases such 
as cancer and are often the best lines of defense[7].  That said, the promise of these 
medicines remains critically viewed due to the high costs of mAb therapies, which 
can exceed $20,000 per year for the treatment of rheumatoid arthritis[8]. 
  
2.1.3 Vaccines 
 Continuing in the theme of immunology, vaccines represent another important 
class of protein therapeutics.  The purpose of vaccines is active immunization, which 
consists of the administration of antigen to a host to induce the formation of 
antibodies and cell-mediated immunity against the administered antigen[9].  While 
there are more than 18 vaccines in current use against infectious diseases, the 
limitation of active immunization is that the host already has been infected and has 
the antigen, thus vaccination with more antigen will not treat active disease.  That 
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said, the importance of vaccines, prophylatically, in healthcare cannot be 
underestimated and the control of vaccine-preventable diseases in preschool children 
is sub-optimal, even in developed nations[10].   
 
2.1.4 Hormone therapy 
 
 Hormonal signals integrate and coordinate the metabolic activities of different 
tissues and optimize the allocation of fuels and precursors to each organ [11].   
Naturally occurring hormones are produced by endocrine glands such as the thyroid, 
adrenal, ovary, testis, pituitary, pancreas and parathyroid glands.  Often, hormone 
replacement therapies, using natural extracts or synthetic equivalents, are necessary 
when an organ stops producing adequate amounts of hormone, as is the case of 
insulin in diabetes.  There are so many hormone replacement therapies on the market, 
the drugs are more appropriately described in detail when associated with specific 
diseases and deficiencies.   For example, there are more than 12 thyroid and 
antithyroid agents available on the market [12]. 
 
2.1.5 Diabetes therapy 
 
 According to the US Centers for Disease Control and prevention, the 
prevalence of diabetes in the United States in 2005 was 20.8 million people or 7% of 
the population.  In 2002, diabetes was the sixth leading cause of death and these 
estimates probably represent under-reporting as death certificates may reflect other 
conditions that actually have diabetes as the underlying cause[13].  When broken 
down by age and ethnicity, the numbers can be even more startling.  It is estimated 
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that 9.6% of people over 20 have diabetes and that ~21% of people over 60 are 
afflicted with the disease.  Non-hispanic whites have the lowest adult incidence at just 
under 9% and non-hispanic blacks are at the high end with an incidence of 13.3%. 
Even more alarming are the rates of occurrence of type II diabetes in children, an 
issue that is closely linked with the obesity crisis [14]. These sobering statistics 
clearly reflect that diabetes has reached an epidemic scale in the US and the financial 
and personal costs are staggering.  The American Diabetes Association, ADA, 
estimated the total costs for diabetes were $98.2 billion in 1997 [15].  
 Nomenclature systems vary but there are currently four distinct types of 
diabetes mellitus (DM).  Type I DM is defined by selective pancreatic ß cell 
destruction and severe or complete insulin deficiency.  Type I disease can be further 
characterized by cause as idiopathic or immune and insulin administration is 
mandatory for these patients [16].  Tissue resistance to insulin and relative deficiency 
in insulin secretion characterizes Type II Diabetes Mellitus.  Insulin is not essential 
for approximately 70% of Type II diabetics but this can change over time and close 
glucose and side effect monitoring is essential.  Type III DM refers to varied other 
causes of elevated glucose such as those seen in the absence of pancreatic disease, 
such as can be seen as a side effect to certain drug therapies.  Lastly, gestational 
diabetes is referred to as Type IV diabetes mellitus in this system of nomenclature.  
Gestational diabetes is diagnosed in approximately 4% of pregnancies in the United 
States. 
 Although the specific treatments can vary greatly by subtype of disease, all 
diabetes treatments have the same goal; to adequately regulate blood glucose in order 
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to prevent the primary and secondary effects of hyperglycemia [17].  As previously 
stated, in Type I diabetes mellitus, this can only be accomplished by the 
administration of insulin.  The latest thinking in the treatment of Type II diabetes 
includes monotherapy using an oral hypoglycemic agent from one of five drug 
classes: sulfonylureas, meglitinides, thiazolidinediones, biguanides and α-glucosidase 
inhibitors [18].  However, studies have shown that after 3 years of treatment, more 
than half these patients will require additional agents for adequate control and most 
type II patients may eventually also require insulin [19].   Treatment in gestational 
diabetes (GDM) may consist of dietary control, the administration of insulin or oral 
hypoglycemic agents.  The oral hypoglycemic agents are used with care however as 
studies have shown increased incidence of pre-eclampsia in patients treated with 
metformin when compared to those treated with insulin [20].  Type III diabetes is, by 
nature, tied to specific etiologies and is treated accordingly and as needed. 
 
2.2 Drug Evaluation 
 Despite the startling technological advances in genetics and biotechnology 
over the last decade, the pharmaceutical and biotechnology industries struggle to 
improve their success rates.  Between 1990 and 2000, the number of new drugs 
launched annually remained essentially constant while the associated research and 
development costs rose by almost 250% [21].  Most failures, 43%, in clinical phases 
I-III, were due to insufficient efficacy.   The next leading cause was toxicity [22].  
Furthermore, 40% of drugs never make it to clinical development as they fail in pre-
clinical development due to issues with absorption, distribution, metabolism and 
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excretion (ADME) [23].  As the costs of drug development skyrocket at the clinical 
development stages, the importance of drug evaluation at the late pre-clinical stages 
cannot be overstated.  Studying the pharmacokinetic and pharmacodynamic profile of 
drug candidates early in high quality bioavailability, toxicity and ADME studies is 
essential to improving the outcomes and safety of clinical trials and these studies are 
appearing earlier and earlier in the drug development process.   
 
2.2.1 Pharmacokinetics and ADME 
 Pharmacokinetic evaluation involves the determination of four essential 
parameters: bioavailability, volume of distribution, half-life and clearance.  There can 
be confusion as to the differences between absorption and bioavailability.  Absorption 
is best defined as the processes that are involved in transferring the drug from the site 
of administration into the venous blood.  Bioavailability differs from absorption in 
that it includes the effects of hepatic metabolism [24].  Mathematically oral absolute 
bioavailability (F) can be defined as: 
 
..)/()( viAUCOralAUCF =     (2.1) 
 
with (AUC)Oral defined as the area under the concentration versus time curve for the 
oral drug dose and (AUC)i.v. is the area under the curve of the concentration versus 
time curve for the i.v. dose [2].  At equilibrium, the volume of distribution (V) can be 
determined from  
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  A = V*C    (2.2) 
where A is the amount of drug in the subject and C is the concentration of drug in the 
plasma.  Immediately following intravenous administration, the volume of drug in the 
body is equal to the administered dose so the volume of distribution can also be 
obtained from the following relationship: 
 
  V = (i.v. dose)/(AUC)k  (2.3) 
 
where k is the first order elimination rate constant.  This relationship also assumes the 
drug follows single compartment pharmacokinetics.  Clearance (CL) measures the 
ability of a body to eliminate a drug and is expressed in the units of flow, volume per 
unit time.  The derivation begins with a model of drug elimination by a single organ, 
which is defined as the extraction ratio (ER): 
 
  ER = (CA-CV)/CA   (2.4) 
 
Where CA is the drug concentration entering arterial blood and CV is the concentration 
leaving the organ via venous blood.  The clearance by an organ CLR can then be 
determined by: 
 
  CLR = QR*ER    (2.5) 
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where QR is the blood flow to the organ.  Lastly, half-life (t1/2) of a drug depends on 
the volume of distribution and the clearance: 
  t1/2 = V/CL.    (2.6)  
 
2.2.2 Pharmacodynamics 
 Pharmacokinetics (PK) describes what the body does to a drug whereas 
pharmacodynamics (PD) describes what the drug does to the body, hence 
pharmacodynamics relates a measured response to the pharmocokinetics of a given 
drug in a given model.  The ultimate goal in understanding the PD for a given system 
is to be able to design an optimized dosage regimen that maximizes the desired 
biological effect obtained by a drug at a given dose and that simultaneously 
minimizes the chance of adverse reactions.  This is refereed to as the therapeutic 
window.  As PD is the measured effects that a drug has on an organism, early efforts 
utilize animal models.  It is typical to progress testing, starting with rodent species, up 
through higher mammals to primates and eventually humans.   In addition, 
computational models of pharmacodynamics have been developed. 
 Gobburu et al have presented some advanced pharmacodynamic mathematical 
models and have applied these constructs to the quantification of the indirect 
pharmacological effects of corticosteroid, diuretic, growth hormone, rh-erythropoietin 
and insulin models [25].  The model applied to insulin kinetics was described by the 
authors as Type IV and is shown in equation 2.7 below: 
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where R is the response, kin the formation rate of the measured response, kout is the 
first order elimination constant, γ is the sigmoidicity, Smax is the maximum fraction of 
inhibition and Cp were the concentrations after intravenous bolus dose or intravenous 
infusion as shown in equations 2.8 and 2.9 respectively. 
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Here kel is the elimination rate constant, V is the volume of distribution and D is the 
dose.  Using this model, the pharmacodynamics of insulin action were compared 
between the subcutaneous, intraperitoneal and steady infusion delivery 
routes/approaches.  The model did approximate experimental data reasonably and the 
importance of dosing in causing indirect pharmacological effects was confirmed. 
 Experimentally, early stage pharmacodynamic studies typically utilize rodent 
and other lower mammal models.  While a detailed treatment is beyond the scope of 
this dissertation, an excellent overview of animal models of diabetes has been 
provides by Sima and Shafrir [26].  In their text, detailed descriptions of more than 17 
animal models of diabetes are presented and well as the characteristics, history and 
example applications of each. 
 Lastly it should be noted that PK and PD data are often presented concurrently 
and interchangeably.  This oversight is not surprising given the complex 
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interrelationships of the two disciplines.  The differences of focus and experimental 
approaches and interpretations are real and complex, however and care must be taken 
in experimental design to ensure the correct interpretation of experimental results. 
 
2.2.3 Toxicity 
 More than 90% of drug withdrawals from the market are due to toxicity [22, 
27].  This has been most often due to undetected/unreported liver and cardiovascular 
toxicities but could also be due to drug-drug interactions.  Given the enormous cost of 
drug development as well as the potentially higher costs in liability to remove a drug 
from the market, toxicity testing is also appearing earlier in the drug discovery and 
development processes.  The challenge is in determining the best definitions and 
testing approaches to determining toxicity. 
 Animal models remain the standard for experimental toxicity testing but how 
good are they?  Some of the best data aggregation in the field of drug hepatotoxicity 
is the output of a joint initiative between representatives from the American 
Association for the study of Liver Diseases, the FDA, NIH and PhRMA, the 
pharmaceutical manufacturers association.  This group presented a study of 214 
human toxicities.  It was found that 71% of these human toxicities could be 
associated with toxicities in animal models.  Sixty-three percent of the toxicities were 
detectable in non-rodent models while 43% were detectable in rodents.  In addition, 
only 36% were detectable in combinations of rodent and non-rodent species.  While 
this sounds encouraging, it should be noted that the actual predictabilities are much 
lower when false positives and false negatives are considered.  In fact, it was 
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determined that only 31/328 or 13% of actual hepatotoxicities were detected with this 
approach, hence all other forms are not included and could be missed [28].  The 
determination of toxicities associated with proteins and biologic therapies can be even 
more problematic as they are frequently immunogenic which can cloud the evaluation 
of toxicity [29].  In fact, the complexities in accurately classifying the potential 
toxicities of biologic drugs is the subject of open petition between the biotechnology 
industry and the FDA [30]. 
In addition to animal models, the utility and promise of in silico and in vitro toxicity 
models continues to grow and latest thinking points towards the need for a combined 
approach to yield optimal results [31].  
 
2.2.4 Toxicity Parameters 
 A standard for toxicity evaluation in drugs is the LD50.  LD refers to lethal 
dose and the LD50 value is defined as the dose at which death is expected in 50% of 
the treated animals [32].  The units of LD50 are typically reported in mass of 
substance per mass of body mass. 
 
2.2.5 in vitro ADME and toxicity screening 
 As it is highly desirable to find alternatives to animal testing that have the 
potential for greater specificity at reduced cost, the field of in vitro ADME/Tox 
prediction continues to grow rapidly.  Over the last three decades models using 
biological material ranging from continuous cell lines to complete embryos have been 
used [33].  In addition, toxicogenomics is a promising emerging field to supplement 
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the pathological, morphological, chemical and biochemical information typically 
collected in in vitro and in vivo studies [34, 35]. 
 
2.2.6 in silico ADME and toxicity modeling 
 In the case of in silico modeling, it appears that there are acceptable 
‘predictive’ computational tools for well-understood mechanisms of toxicity such as 
mutagenicity or skin sensitivities but analogous models do not yet exist for more 
mechanistically complex situations such as acute and chronic organ toxicities [36, 
37].   
 
2.2.7 In vitro models of intestinal absorption 
 In an attempt to model in vivo situations in a quick and inexpensive fashion, in 
vitro models of intestinal transport and drug absorption have been developed.  These 
models typically utilize purified human or mammalian cell lines to simulate whole 
tissues and organs.  The cells can be developed rather quickly, grown in quantity as 
needed and offer a humane and cost effective alternative method to facilitate the rapid 
screening of many compounds.  Early work focused on obtaining intestinal brush 
border membrane vesicles (BBMV) and similar biomembranes [38].  Using these 
membrane vesicles, it was soon shown that peptide transport was independent of 
sodium concentration and occurred by a ‘non-concentrative’ mechanism [39].  This 
study may have been one of the earliest studies demonstrating active transport.  It was 
later shown that thyrotropin-releasing hormone (TRH) uptake in BBMVs was most 
likely also passive [40].  These types of studies were reasonable simulations of what 
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happens within the brush border but mammalian cells are far more complex than 
membrane vesicles and better models were needed. 
Shortly after these early studies, an excellent review of the enhancement of 
intestinal absorption was published by van Hoggdalem et al.[41].  This work 
summarized the in vivo work to date and was followed by studies that began to 
quantify and qualify the transport parameters for small peptide drugs. At this time, in 
situ animal models were still in play.  It was soon shown that passive and non-passive 
(paracellular and transcellular) transport are independent and can occur 
simultaneously [42].  One key early study on insulin absorption examined the effects 
of the variations of tissue morphology and enzymatic makeup through the length of 
the intestines.  It was shown that the jejunum and the ileum were preferable sites for 
insulin absorption compared to the duodenum [43].  Similar conclusions were reached 
in analogous studies using oxytocin and vasopressin.  It was theorized that the distal 
segments of the intestines have a higher level of paracellular permeability [44].  A 
later study by Ungell et al. characterized the permeability of 19 drugs across three 
regions of rat intestine.  The results showed correlation between the drug molecular 
weight, hydrophilicity or hydrophobicity and absorption in these regions of the 
intestine in the hope of developing an accurate analytical tool to predict the 
absorptivity of modeled compounds [45].  Another important step in the development 
of in vitro transport models was the necessary mathematical treatment of the transport 
itself.  Sinko et al proposed a reasonable model in 1993 that was based upon 
convection, permeability and chemical reaction [46]. 
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 One of the earliest in vitro models was the Caco-2 cell line.  This cell line was 
isolated from a primary colonic tumor at the Memorial Sloan Kettering Cancer Center 
in New York City [47].  This cell line has become the standard in the modeling of in 
vitro intestinal transport and some of the specifics of this cell line are covered in the 
next section.  Early work with the Caco-2 line evaluated the transport of bile acids.  It 
was found that the transport of taurocholic acid was dependent on time in culture and 
that the apical (AP) to basolateral (BL) transport was 10 times greater than the BL-to-
AP transport [48].  That same year, work was done to compare the Caco-2 cell line 
model with the in vivo closed loop approach and it was found that the cell monolayer 
provided a reasonable approximation of the expected permeability seen with the in 
situ system for a specific family of peptides [49].   
 Since then, the Caco-2 model has become the mainstay of in vitro intestinal 
transport science.  Transport of many proteins and large molecules have been 
evaluated and optimized including erythropoietin, granulocyte stimulating factor 
(GSF), nanoparticles, various antibiotics, cosalene (a potent inhibitor of HIV 
replication), benzo[a]pyrene metabolites, leuprolide just to name a few examples that 
have been published in the public domain [50-54].  As this cell line enjoyed a brief 
period of favor in the pharmaceutical and biopharmaceutical industries in the late 
1990s, it is a good assumption that the absorption properties of countless small and 
large molecules have been studied in this cell line.  It should also be noted that many 
of these papers focused on the ability of vitamin B12 to mediate and improve uptake 
and transport in this cell line.  In 1996, Quaroni et al. provided an excellent review of 
the development, state, benefits and challenges of using cell culture models for drug 
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transport and metabolism studies [55].   They concluded that there were three well-
established and relatively credible in vitro cell models, each having its own 
limitations.  They were the IEC-type cell lines, the only ‘normal’ cell model, and the 
Caco-2 and the mucin producing HT-29 cells.   The reader can consult this reference 
for a more detailed treatment of the technology and usage up to that time.  Lastly, in 
the decade since the previously mentioned review it should be noted that the utility of 
many in vitro cell line models, while still in use, is still being questioned relative to in 
vivo data and approaches [56].  
  
2.2.8 Caco-2 Model Development and Characteristics 
 Bailey et al presented a detailed review of the utility of the Caco-2 cell line 
over a decade ago.  Most interesting in this review were the correlations presented 
between permeability, bioavailability and partition coefficients for molecules with 
molecular weights under 600 [57].  While the review is excellent, the focus on small 
molecule drugs makes the findings only indirectly applicable to protein therapeutics.    
There have been attempts to mathematically model the Caco-2 system.  In one 
attempt to model diffusion and partitioning, it was determined that the caco-2 model 
fit somewhere in between the artificial membrane models of 1-octanol and 
isopropylmyristate systems.   Theoretically, this is clearly less than predictive with 
reasonable precision [58].  There are also many instances of comparison studies 
between the Caco-2 model and other intestinal models.  Each appears to have its own 
merits and downsides.  In one model, the IEC-18 cell line, a low-resistance rat model, 
was compared with Caco-2 cells and was shown to exhibit similar transport profiles 
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with lipophilic compounds but increased rates of transport of hydrophobic 
compounds transported paracellularly [59].   Articles of this type highlight the fact 
that the Caco-2 model is clearly the standard of choice. 
 As the standard, there has been a significant amount of work focused on 
optimizing this model.  Approaches to optimization include: evolving the model to 
establish a mucous barrier, the utilization of simulated intestinal fluids to remove the 
non-ideality of HBSS transport buffers, using mixtures of analytes to obtain higher 
throughput, development of more rapid, reduced serum culture systems and the 
quantifying effects of using transport enhancers [60-65].  Each of these works offered 
its own improvements but each was also very specific to the culture conditions, the 
drug molecules studied and the transport mechanism, active or passive, studied.  
Lastly, a solid general overview of the effects of culture conditions including seeding 
density, number of passages, split ratios and time to confluence has been provided by 
Behrens et al [66].  It should be noted that the approach from this particular article 
were strongly incorporated into the Caco-2 culture methods utilized in this research. 
 
2.3 Protein and peptide drug delivery 
 Most protein and peptide drugs are labeled exclusively for parenteral 
administration.  A parenteral drug formulation may be administered as a continuous 
intravenous (i.v.) infusion, injected intramuscularly (i.m.) or injected subcutaneously 
(s.c.) [2].  This is due to the significant barriers to oral administration such as liver 
metabolism, enzymatic degradation, very short drug half-lives and other 
pharmacokinetic and pharmacodynamic deficiencies.  
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2.3.1 Challenges of parenteral administration 
 Despite being the standard of care for most protein therapeutics, parenteral 
drug delivery of novel biologics presents significant issues of cost, efficacy and 
compliance.  The costs are staggering.  It is estimated that, cost sharing for biologics, 
the patient co-pay, could reach up to $1000 per dose as opposed to $15-$50 for other 
medications and the annual cost per patient for the biologic treatment of some chronic 
diseases could reach $35,000 [67].  The products themselves can be extremely 
expensive to make and, as most parenteral drug administration must be performed by 
or under the supervision of a specially trained healthcare professional, the treatments 
have often been tied to medical office and clinic visits, which further add to the cost 
of these therapies [68].  Managed care has responded with specialty pharmacy 
networks and a strong push towards the availability of self-administered injectables.   
While not nearly as expensive or as difficult to deliver, the purely human 
aspects are critically important variables in this equation when insulin delivery is 
considered.  A recent study showed that up to 65% of patients with type 1 and type 2 
diabetes, in clinical trials to assess self-delivery devices, were not confident in their 
ability to effectively self-manage their disease and as many as 25% of these folks 
described anxiety with respect to self-injection [69].  Lastly, there is a significant 
unmet medical need for novel drug delivery systems in pediatric care where lack of 
age appropriate drug formulations often leads to the off-label use of adult drug 
delivery approaches[70].   
 
 23
2.3.2 Pumps and implantable devices 
 As so much work has been done on optimizing alternatives for insulin 
therapy, the state of personal infusion pumps can be studied by focus on insulin 
delivery. Insulin Pumps have been in use to deliver insulin subcutaneously to diabetic 
patients since the 1970s and it is estimated that pump usage in developed countries 
such as the US may be used by up to 20% of type 1 diabetes patients [71].  The 
primary advantages realized to date with continuous subcutaneous insulin infusion 
(CSII) are improved nocturnal glycemic control, a minimization of the pre-breakfast 
blood glucose increase, a decrease in frequency of hypoglycemia and lower mean 
glucose concentrations [72].  The major challenges to the application of this approach 
to wider patient populations are suitability of specific diabetes disease states, the 
inability of certain patients to manage the technical details and complexities of CSII, 
the inability of pumps to utilize continuous glucose monitoring and high costs [73]. 
 The physical implementation of the continuous infusion pump is relatively 
simple and consistent.  The pump is a small, battery-powered, external device that 
administers insulin through a subcutaneous catheter.  Insulin can be administered at a 
slow constant rate and bolus doses can be given before meals or at other times as 
desired.  Although this simple design approach has become a successful standard of 
care for a large patient population, the unmet opportunity lies in the fact that this 
open-loop approach is sub-optimal.  In an open-loop system, the device is externally 
regulated and controlled.  There is no feedback mechanism that enables a response to 
a given stimuli.  In the case of CSII, this means that a pump is simply programmed to 
deliver a certain volume of insulin over a certain period of time or as controlled bursts 
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of prescribed duration.  The pump has no awareness of the blood glucose or insulin 
levels in a patient.  The more idealized device is a closed loop system where the 
principles of CSII are combined with continuous glucose monitoring.  In effect, this 
concept approaches the ideal of an artificial pancreas.  There are two closed-loop 
approaches in development.  There is the s.c.-s.c. approach, where subcutaneous 
glucose monitoring is combined with CSII as well as an implantable i.v.-i.p., where 
intravenous blood sampling is combined with intraperitoneal insulin delivery [74].   
Although progress is being made, to date, the glucose monitoring capability remains 
the limiting factor in the development of such a system [75, 76].  The complexity and 
variability of glucose control in diabetes make the development of a generic delivery 
algorithm that is capable of providing adequate closed-loop control challenging [77].  
Lastly, the use of pumps in treating diabetes is on the rise.  A standard of care for 
diabetes in children has been published and guidelines to assist families and medical 
professionals in deciding which children could benefit from the use of insulin pumps 
are effectively in use [78]. 
 Some of the latest breaking options in protein delivery have been enabled by 
the growth and realization in the fields of micro-and nano-technology.  Miniscule 
electro-mechanical devices for drug delivery are becoming feasible.  An example of 
the possible implementation of this type of system is also an idealized artificial 
pancreas where a small-scale biosensor and drug reservoir are combined and 
implanted to achieve a wireless and integrated system for drug release [79].  Systems 
under development include an implantable microchip device that contains an array of 
discrete mini reservoirs.  Drug release from thee reservoirs can be controlled via 
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telemetry.  Promising pharmacokinetic results were obtained when this system was 
applied to the pulsatile release of leuprolide, a hormone currently marketed for the 
treatment of endometriosis and prostate cancer [80]. 
 
2.3.3 Drug-eluting stents  
 Although most applications of drug-eluting stents (DES) have involved the 
use of small molecule therapeutics, this exciting example of the emerging field of 
combination products (drug/device) will most likely be utilized extensively in the 
targeted delivery of protein therapeutics.  Metallic scaffolds, stents, have been used to 
prevent restenosis of blood vessels following balloon angioplasty.  On their own, 
these stents helped manage balloon induced vascular damage but there were side 
effects such as damage to the blood vessel wall and inflammatory responses such as 
in-stent-restenosis [81].  As systemic drug treatments of these side effects were 
inadequate, using the stents themselves as a localized delivery platform solved the 
issue.  The results have been startling and more than 2.5 million stents had been 
implanted as of February 2005 [82].  The realized benefits include higher drug levels 
in the local tissues, lower risk of systemic drug toxicities and controlled release of the 
therapeutic agent over a prolonged period of time.  The wide variety of mechanisms 
of controlled drug release have been successfully employed in stents include 
diffusion, dissolution or degradation, ion exchange and prodrug based systems [83].  
These different mechanisms are enabled by the application of specific coatings to the 
stents.  In addition, stent manufacturers have taken steps to improve biocompatibility.  
These include heparin and phosphorylcholine coatings as well as anti-body eluting 
 26
stents.  In one of the earliest applications of stents incorporating antibody delivery, it 
was shown that when monoclonal platelet GP IIb/IIIa receptor antibody AZ1 was 
eluted from a polymer-coated coronary artery stent in rabbits, platelet deposition was 
significantly reduced, cyclic blood flow variation was almost eliminated and mean 
blood flow and arterial patency rates were improved [84].  The success of these 
devices is startling and unprecedented.  Currently, almost 90% of stent patients 
receive drug-eluting stents and the frequency of coronary bypass surgery has actually 
begun to decline for the first time since its introduction [85]. 
 
2.3.4 Ocular delivery systems  
 Since the early 1980’s there has been significant interest in the study of 
protein and peptide drug delivery via the eye as an alternative to parenteral 
administration as it could be more cost effective, offer more rapid blood 
concentration, avoids the first pass hepatic effect as the compounds bypass portal 
circulation to the liver, offers precise dosing and simplicity of monitoring for side 
effects [86].  This promise has led to the study of the eye as a delivery route for many 
drugs such as ACTH, calcitonin, β-endorphin, glucagons, LHRH, oxytocin, 
somatostatin, vasopressin and others including insulin [2].  The most promising 
results typically were found in the presence of various absorption enhancers [87].  
These enhancers are used to overcome barriers to the eye as a route for protein 
delivery.  These barriers include tissue compartments and cross-ocular blood barriers 
as well as enzymes that are capable of degrading the drugs [88].  As the tissue of the 
discrete eye compartments is not homogeneous, specific pharmacokinetic models 
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have been proposed to aid in the understanding of ocular drug transport [89].  Similar 
to the case of intestinal absorption, the key to optimizing this route of delivery 
appears to lie with understanding and exploiting active transport receptors and 
processes [90]. 
 
2.3.5 Transdermal protein delivery 
 Drug delivery via the skin holds similar promise to other non-parenteral 
routes: high patient compliance, low costs, pain-free, easy maintenance and 
observations as well as possible avoidance of first pass hepatic metabolism.  That 
said, the realization of these possibilities has been slow to come primarily due to the 
core purpose of skin, to provide a low permeability protective coating for the body 
[91, 92].  There have been successes, however, especially with low molecular weight 
(MW<500 Da) lipophilic drugs.  Transdermal estradiol patches are used by more than 
1 million patients per year and are not associated with the liver damage that has been 
see with oral formulations [93].  Similarly, the success of nicotine patches as an aid to 
the cessation of smoking is startling [94].  Despite these successes, the untapped 
potential of this route of drug administration is perceived to be very high.  Current 
work focuses on various absorption enhancers, such as pressure waves, microneedles, 
sonophoresis, chemical enhancers, iontophoresis, electroporation and the use of lipid 
vesicles, any of which may hold the key to success [95]. 
 It has been reported that a single pressure wave, generated by intense laser 
radiation, is sufficient to permeabilize the stratum corneum of the skin and enable the 
transport of macromolecules.  Using multiple pressure waves, there has been success 
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in delivering therapeutic levels of insulin to rats [96].  Hollow microneedles are 
another approach to transport enhancement.  Using arrays of needles to gently pierce 
the skin, diffusion rates of drugs can be improved.  Current work includes the study 
of both solid and biodegradable microneedles [97, 98].  The utilization of ultrasound, 
sonophoresis, as an enhancer of skin permeability has had success in delivering 
insulin, erythropoeitin and γ-interferon in in vitro studies in cadavers and in vivo 
animal models [99, 100].  Chemical penetration enhancers have shown utility and 
promise.  These range from small molecule solvents such as water and urea to 
complex proteins, colloids and lipid vesicles [101, 102].  The key complexity with 
this approach appears to be a lack of generality due to the tight specificity of each 
drug to an optimal penetration enhancer [103].  Electroporation is a transitory 
structural perturbation of lipid bilayers by the application of pulses of high voltage 
electricity.  This technique has been shown to increase the transport across the skin 
for some high molecular weight molecules [104].  Arguably, the most promising 
approach to date is iontophoretic drug delivery.  This technique employs a small 
electrical potential to achieve a constant electrical current across an area of skin.  The 
resulting amount of drug delivered is directly proportional to the quantity of charge 
passed, the duration of application of current and area of skin surface in contact with 
the active electrode compartment [105].  This approach has been investigated for 
utility in insulin delivery as well as for the delivery of many other therapeutic agents 
and Alza has recently received FDA approval to market IONSYS™, an iontophretic 
device for fentanyl delivery [106, 107]. 
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2.3.6 Inhalant and mucosal protein delivery 
 As parenteral routes of delivery remain the standard of care due to the 
significant barriers to non-parenteral absorption which include enzymatic and 
physical obstacles, mucosal and pulmonary routes of delivery are also of interest 
[108, 109].  The lung is a somewhat idealized delivery target due to the wide array of 
receptors expressed by the pulmonary tissues [110].  Success has been had in 
delivering peptides through the pulmonary system as demopressin and salmon 
calcitonin are currently commercially marketed as nasal spray formulations [2]. 
Pulmonary and specifically, nasal, drug delivery offers the potential benefits, and 
possible unwanted side effects, of local and systemic drug absorption.  The obvious 
example of this are the cases of intranasal corticosteroids used in treating bronchial 
asthma and allergic rhinitis where the pharmacokinetics and pharmacodynamics have 
been documented [111, 112].  Pulmonary drug absorption varies based upon the 
physical properties of the drug as well as lung deposition which depends upon these 
physical properties as well as the state of the respiratory system [113].   
 The fact that the pulmonary system serves as an entrance point for so many 
diseases can also be applied to obtain advances in drug delivery technology.  For 
example, induction of mucosal immunity may be an important tool in the prevention 
of serious public heath challenges such as severe acute respiratory syndrome (SARS) 
[114].  The ability of drugs absorbed through the pulmonary system to elicit an 
immune response is similarly being studied in combined mucosal/parenteral delivery 
studies for vaccination against HIV and influenza [115-117].  The diversity of 
opportunity around pulmonary delivery can be accentuated by the consideration of 
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some recent studies which utilize aerosol therapies as delivery approaches for gene 
therapy in lung cancer [118].   
 Of specific interest to me is the study of nasal insulin formulations.  The 
recent FDA approval of an inhaled human insulin product, Exubera™ (Pfizer, NY, 
NY), has brought the dream of delivery more complex proteins nasally to fruition.  A 
wealth of knowledge was obtained during the development of this product that can be 
generally applied to other nasal delivery applications.  For example, it was 
determined that tight control of drug particle size is essential for delivery with the 
optimum aerodynamic diameter for drug delivery via alveoli being 1-3 µm.  Larger 
particles tended to be trapped and deposited on the oropharynx and the upper airway 
before reaching the alveoli and smaller particles were often lost during exhalation 
[119].  The onset of action for inhaled insulin is significantly faster than that of 
subcutaneously administered human insulin but the duration of glucose lowering 
activity was similar [120].  Despite the optimism of this revolutionary product, 
questions remain about long-term safety, specifically with respect to insulin buildup 
within the lungs [121].  As promising as the nasal route appears, there is clear 
opportunity for better alternatives. 
 
2.4 Oral protein delivery  
 Holding the promise of decreased healthcare costs, increased patient 
compliance and superior safety and pharmacokinetic profiles, the interest and demand 
for oral peptide and protein delivery systems is very high [122]. The disadvantages 
and challenges of parenteral protein administration were outlined in detail earlier.  
 31
Unfortunately, parenteral administration remains the standard of care as the barriers 
to oral protein delivery remain more significant and insurmountable to those of 
conventional delivery.  In order to have adequate bioavailability, a protein drug must 
pass safely through the low pH and protease-rich environment of the upper 
gastrointestinal tract, across the mucous lining of and then across/through the 
intestinal epithelial lining and into the blood stream.  Once into the intestinal capillary 
system, the drug must still survive a pass through the liver in adequate quantity to 
ensure adequate drug bioavailability as shown in Figure 2.1.  These significant 
barriers will be discussed in detail in the following sections. 
 
2.4.1 Chemical and Biochemical Barriers to Oral delivery 
 After oral ingestion, protein drugs must pass through the stomach intact.  The 
definition of intact for complex protein therapeutics includes all four levels of protein 
structure including complex conformations [11].  The gastric juice of the stomach 
contains a family of aspartic proteinases called pepsins, which are most active at pH 
2.0 - 3.0.  Pepsins function by breaking proteins down into polypeptides, which are 
then passed to the duodenum.  As the polypeptides and remaining proteins pass into 
the duodenum, there is s sharp rise in pH, which could cause the protein to precipitate  
if it passes through its isoelectric point.  In the duodenum, pancreatic enzymes, such 
as trypsin, chymotrypsin and carboxypeptidase A, attack the proteins [123].  As the 
proteins reach the brush border they are acted upon by exopeptidases as well as 
lyosomes and other organelles that can act as sites of protein degradation [124].  It is 
estimated that more than 90% of the proteolytic activity of the small intestine occurs 
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at the brush border membrane.  The distribution of brush border enzymes is variable 
throughout the jejunum and small intestine and profiles of this distribution have been 
studied as potential variables to be exploited for protein delivery [125-127].   
The mucous lining of the gastrointestinal tract also offers physical barriers to protein 
transport.  As a visco-elastic gel, the mucous lining ensures that food contents/chyme 
move smoothly through the intestines to prevent damage caused by caustic agents.  
Not only does the mucous layer offer a mechanical obstacle as protein drugs can slide 
past and through without adequate contact with the intestinal brush border, the 
glycoprotein matrix of the gel itself can be a physical obstacle to protein transport and 
uptake [128].   
The drug that passes through the system unabsorbed is lost in feces.  When 
taken in total, the chemical and enzymatic barriers to protein drug delivery via the 
gastrointestinal tract remain almost as formidable as reported more than 15 years ago 
[129]. 
 
2.4.2 Cellular Barriers to Oral delivery 
 
 Once a protein therapeutic has been successful in surviving the biochemical 
environment of the stomach jejunum and brush border it may come into physical 
contact with the epithelial lining of the small intestine, which presents the next 
obstacle.  A schematic and the possible routes of protein transport across an idealized 
epithelial cell monolayer is shown in Figure 2.2.   The possibilities for successful 
transport are passive transcellular transport, passive paracellular transport, carrier-
mediated uptake and carrier mediated efflux [130].  Transcellular transport requires 
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that proteins cross over through cell membranes passively or actively and paracellular 
transport covers the cases where molecules can cross the membrane by moving 
between the tight intracellular junctions.  These tight junctions (TJ) completely 
circumnavigate each epithelial cell to form a continuous seal that separates the apical 
and basolateral membrane components.   
Tight junctions serve the essential purposes of providing a barrier to random 
paracellular transport of components and ensure the availability of a selective 
intestinal transport pathway.  Tight junctions are complex structures of strands that 
have been described as intramembranous, cylindrical, inverted micelles that appear to 
result from the linear fusion between the plasma membranes of epithelial cells [131, 
132].  Groups of proteins, called claudins and occludins form the primary TJ seal  
[133].  These TJ structures appear to act with another cell-cell contact system called 
the adherin junction (TJ) and it is a complex of TJ and AJ components that appear to 
anchor cytoskeletal components [134].  While providing a region of opportunity for 
mechanisms of epithelial transport, this must be done very cautiously as specific 
health issues may arise from chronic disruption of the TJ barrier [135-140]. 
Transcellular transport involves intracellular transfer from the apical surface 
of a cell through the cytosol and across the basolateral cell surface.  For lipophilic 
drugs, this process can happen passively via a series of partitioning events [2].  In the 
case of sugars and amino acids, a carrier-mediated process in required [141].  This 
carrier-mediated process can be somewhat enigmatic.  If the native epithelial cell 
membrane already contains a receptor for the targeted drug, then the transporter can 
work as designed.  However, this is seldom the case for most synthetic and many 
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naturally occurring proteins and peptides.  Needless to say, the barriers to 
transcellular transport are most formidable with the apical membrane being the rate-
limiting step [142].  The selectivity of these transporters is critical to normal cellular 
function as the selectivity of transporters effectively regulate the pharmacological, 
and, potentially, toxicological effects of drugs by limiting the distribution of these 
substances to tissues and the blood stream [143].  These processes are extremely 
complex and the current understanding and hypothesis of the transcellular 
components of insulin transport across intestinal epithelium will be covered in later 
sections. 
 
 
2.4.3 Hepatic Barriers to Oral delivery 
 
 As a key mechanism of drug clearance, the hepatic system poses a 
quantifiable barrier to bioavailability as drugs entering the venous capillaries will 
pass through the liver prior to becoming systemically available via arterial blood 
[142].  The hepatic clearance has historically been predicted via in vivo 
methodologies in combination with in vitro studies using using hepatocytes, hepatic 
microsomes and/or liver slices [144-146].  In truth, there is little that could, or should, 
be done to decrease or eliminate hepatic clearance of drugs to increase bioavailability 
as the homeostasis of liver function must be preserved to ensure health and well 
being.   
 
2.4.4 Commercial Barriers 
 
 Another important, if non-intuitive, aspect of the feasibility of oral protein 
drugs is the economical impact.  The promise of oral delivery presents a dichotomy in 
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that it is unclear who, if anyone, would benefit most.  As biotechnology drugs are so 
complex, the method of administration is part of the specific license to market and 
label approved by the FDA in the US and foreign regulatory agencies abroad.  This is 
primarily due to the complexities of demonstrating bio-equivalence between various 
formulations of a complex biological product [147].  This raises the question as to 
whether the introduction of a new formulation/delivery methodology can actually 
extend the patent life of a drug and/or be a way to deter competition from biological 
generics or biosimilars [148, 149].  This may, in fact, be necessary to make non-
parenteral routes of delivery a reality for complex biological products. 
 The challenge lies in the complexity of manufacturing these drugs and the 
resulting eventual costs to the healthcare systems and consumers.  The list of 
challenges is amazing, as the more successful a product becomes, the tighter the 
bottleneck that appears on the manufacturing end and, eventually, the higher prices 
soar [150].  This sets up a critical dependency between drug delivery and pricing with 
bioavailability as the relating factor.  For example, if a major price driver for a protein 
therapeutic is the cost of manufacture, is it economically realistic to choose to deliver 
the drug to the patient orally or transdermally when 90% of the actual drug may be 
lost via the barriers discussed earlier in this chapter?  Even with the costs of setting up 
infusion clinics and other necessities of parenteral administration, direct injections 
may prove to be the most cost effective treatment options.  The recent approval of 
inhalable insulin, EXUBERA™, should serve as the first test of this complex 
economic picture.  Will it be a commercial and medical success? 
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2.5 Options for Improving Oral Delivery 
 
 Despite the previously outlined challenges and barriers, there have been 
numerous innovative approaches taken to get around these obstacles and deliver on 
the promise of oral protein delivery.  The following sections will detail many of these 
approaches with a specific bias towards the applications of these approaches to 
metabolic therapy and insulin delivery. 
 
2.5.1 Chemical Modification 
 
 Chemical modification refers to actions taken to chemically alter or modify 
the drug properties to improve oral bioavailability, PK and/or PD without any 
resultant changes in drug function.  Given the assumption that idealized properties for 
intestinal absorption can be described, a roadmap for chemical modification can be 
applied [151-153].  These include inclusion of small molecule carrier solutions, 
optimization of size, charge and hydrophobicity, lipophilicity, physical optimization 
of protein to the requirements of a specific transporter, octanol:water partition 
coefficients, N- and C- terminal modifications, prodrug approaches, peptidomimetic 
approaches, co-administration and/or incorporation of peptidase inhibitors, partial 
unfolding and several other approaches [154, 155].  Generally, these techniques are 
more successful with peptides than complete proteins due to the differences in 
molecular complexity. 
 Examples of protein modification attempts can be found across a range of 
therapeutic proteins.  Conjugation of proteins to peptides and other molecules is an 
area of specific interest and intense study.  A polycarbophil-cysteine conjugate 
system was utilized along with glutathione, a permeation mediator, to demonstrate an 
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improvement in the oral bioavailability of low molecular weight heparin [156].  A 
glutathione-mediated mechanism of action for this system has been attributed to 
inhibition of the closing of tight junctions via the thiol groups of the polymer [157].  
Thiol chemistry was similarly important to an approach that utilized a chitosan-
pepstatin conjugate to target calcitonin delivery to the stomach [158].  Using another 
approach, studies have demonstrated that conjugation of lipidic amino acids to poorly 
absorbed drugs to increase in lipophilicity can increase uptake [159].  This approach 
has showed promise in the case of the enzymatically labile proteins luteinizing 
hormone releasing hormone and thyrotropin releasing hormone [160].  This concept 
of application of peptides to increase drug uptake has also been applied to the specific 
task of cell penetration and continues to be an area of optimism due to the distinct 
specificity that this approach can afford[161, 162].  Salmon calcitonin has been 
utilized as a model drug for lipidization studies as well and, in the case of mice and 
rats, improved pharmacokinetics were obtained as well as improvements in 
pharmacodynamic models of osteoporosis [163].  Lastly, not quite the same as 
chemical modification, the use of absorption enhancers is of interest [164, 165].   
 Insulin has been the target of chemical modification in attempts to improve 
oral bioavailability as well as to alter its pharmacokinetic and pharmacodynamic 
properties.  Early studies focused on the use of physiologic surfactants, such as 
sodium dodecyl sulfate (SDS), to improve enteral absorption [166].  Cyclodextrins 
were also examined by the same group as chemo-protectants and absorption 
promoters with mixed results in rodent models [167].  Acylation is another area that 
has been studied as a possible area of opportunity to improve enteral absorption of 
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insulin.  It was shown, however, that acylation did not improve intestinal absorption 
but that insulin uptake in the large intestine could be improved by increasing the 
number of caproic acid molecules attached to insulin [168, 169].  Lastly insulin 
analogues have been developed and are available as parenteral formulations to 
provide varying pharmacodynamic profiles, which can be of benefit to specific 
patient groups [170, 171].  
 
2.5.2 Protease Inhibitors 
 
 Another approach to improving the oral bioavailability of protein therapeutics 
is to protect the drug from proteolytic degradation by inhibiting or reducing the action 
of the various enzymes that are capable of deactivating the molecule.  Qualitatively, 
the enzymatic barrier to drug absorption is defined by the structure of the protein 
which is being orally administered.  Selection of inhibitors must then be very specific 
against the specific enzymatic barriers [172]. As this approach is not limited to 
attempts to enhance oral delivery, it has been studied extensively.  Many molecules 
have been evaluated as potential absorption enhancers including nafamostat mesilate, 
bacitracin, soybean trypsin inhibitor, chymostatin, potato carboxy peptidase inhibitor, 
phosphoramidon, antipain, leupeptin, bestatin, foroxymithin, amastatin, aprotonin, 
nafamostat, Tos-Lys-chloromethylketone, Tos-Phe-chloromethylketone, 3,4-
dichloroisocumarin, trans-epoxysuccinyl-leucylamido (4-guanido) butane and 
diisopropyl fluorophosphate (DFP) [173].   
 Various methods of administration have been attempted and some possible 
excipients themselves have been evaluated for their inhibitory properties.  In an 
attempt to inhibit trypsin, starch–g-poly(acrylic acid) copolymers and 
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starch/poly(acrylic acid) mixtures were evaluated using Carobopol® 934P as the 
reference polymer for Ca2+ and Zn2+ binding and enzyme inhibition was observed 
[174].  Chitosans have also been chemically modified to serve as enzyme inhibitors 
and have shown inhibitory effects against pancreatic serine proteases [175].  There 
are many other examples including combination studies using multiple inhibitors that 
date back to the early 1990s [176]. 
 There has been a significant volume of work focused on improving insulin 
intestinal absorption and enteral bioavailability using protease inhibitors.  Early 
studies using closed loop intestinal models in the large intestine demonstrated 
successful significant increases in hypoglycemic effect when insulin was co-
administered with 20mM of Na-glycholate, chemostat mesilate and bacitracin [177].  
The same study concluded that soybean trypsin inhibitor and aprotonin improved 
insulin absorption in the small intestine.  In in vitro models, hyaluronidase has been 
used to actually temporarily diminish the mucous/glycocalyx layer to remove the 
physical and enzymatic barriers to intestinal transport of insulin [178].  Similarly, 
studies have shown that co-administration of the protease inhibitor, aprotonin, 
increased the pharmacodynamic effect even more [179].  Lastly, there has been effort 
applied to enzyme inhibitors to protective polymeric delivery systems.  Conjugates of 
the mucoadhesive polymer sodium carboxymethylcellulose with the Bowman-Birk 
inhibitor (BBI) showed strong inhibitory activity against trypsin and chymotrypsin 
and polymer-elastinal conjugates demonstrated better inhibitory activity against 
elastase [180].  This study further accentuates the role of specificity in the success of 
these approaches. 
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2.5.3 Mechanistic enhancers 
 
 An alternative method to increase drug absorption is to design strategies that 
target specific mechanisms within the cellular and intracellular armor itself.  
Previously mentioned examples of this approach applied to non-oral systems include 
the iontophoretic delivery approach for drug transport across the skin.  In this case, an 
electrical current is used to temporarily and reversibly make the skin more permeable 
to therapeutic agents [105].  One analogous approach to the enhancement of oral drug 
delivery is to alter paracellular drug transport via manipulation of tight junctions.   
 A model of tight junction structure is presented in Figure 2.3.  The tight 
junction is a multiple unit structure composed of a multiprotein complex consisting of 
transmembrane proteins; occluding and claudin and cytoplasmic plaque proteins; ZO-
1, ZO-2, ZO-3, cingulin and 7H6 that are affiliated with an underlying apical 
actomyosin ring [137, 181].  In vitro and in vivo studies using Zonula Occludens 
toxin (Zot) and its biologically active fragment, ∆G as absorption enhancers, have 
shown promise in the ability to transport paracellular markers and previously poorly 
absorbed drugs across the intestinal epithelium [137].  This approach has been 
utilized in combination with the enymatic degradation inhibitors bestatin, captopril 
and leupeptin to demonstrate significant increases, 200%-5000%, in the oral 
bioavailability of radiolabeled cyclosporin, ritonavir, saquinavir and acyclovir when 
administered intraduodenally [182].  Similar studies have been done to demonstrate 
the ability of ∆G to enhance the paracellular transport and oral absorption of mannitol 
[183, 184].  Similarly, the ability of Zot to reversibly open tight junctions has been 
studied in the application to bovine brain microvessels to enhance transport of 
 41
molecular weight markers and anti-cancer chemotherapeutic agents, such as 
[3H]doxorubicin, MTX and paclitaxel with some success [185, 186].  Zot has also 
been evaluated as a mucosal adjuvant to induce protective immune responses for the 
application of vaccine delivery [187].  Despite the promising results, there are 
concerns regarding the unintended negative consequences of tight junction function 
[188].  Most of these studies have tested cellular toxicity but the physiological effects 
of tight junction disruption in in vivo studies is seldom cited.  As previously 
mentioned there are many mal-absorption illnesses associated with altered intestinal 
permeability and similar concerns have been raised for applications of drug delivery 
enhancement to airway epithelia.  Targeting the occluding proteins directly has been 
studied as a potentially less toxic alternative [189].  Lastly, as described in section 
2.4.2, a potentially more promising mechanistic approach is to target specific cell 
membrane carrier enzymes for active transcellular transport and several interesting in 
vitro screening approaches have been developed [190, 191].   
 
 
 
2.5.4 Site Specific Drug Delivery: Colonic, Lymphatic and Others 
 
 In this section the concept of enhancing bioavailability by targeting 
therapeutics to specific organ and tissues via oral and other routes of administration 
are discussed.  The colon is one such commonly targeted organ.  Typically a carrier 
system, such as those that will be discussed in the next section, is employed to enable 
safe passage of the drug through the stomach and small intestine [192].  One reason to 
target a specific organ is to treat organ-specific diseases locally.  One example is the 
design and use of polymer conjugates to bring colon cancer therapies directly to the 
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colon following oral administration [193].  Alternatively, the varying regions of the 
intestinal system may be targeted as absorption varies geographically throughout the 
tract [194, 195].  The differences may be attributable to differences in the distribution 
of cellular receptor sites, mucous thickness, differences in tissue permeability and 
mass transport challenges due to chyme and fecal matter [196].  Lastly, the slow 
moving environment of the colon may make it ideal for certain therapeutic situations 
[197]. 
Once to the colon, whether the drug was administered orally or rectally, a 
variety of techniques to enhance absorption and bioavailability have been employed.   
Absorption enhancers, protease inhibitors, enteric coatings and chemical modification 
have all been tried [198, 199].  In the case of insulin, it has been shown that 
absorption enhancers such as surfactants, bile acids, phospholipids, enamine 
derivatives and sodium salicylate derivatives are necessary to obtain reasonable 
bioavailability [200, 201].  Insulin absorption studies in the ascending colon of rats 
using a polymer, N-diethyl methyl chitosan (DEMC) as an absorption enhancer to 
loosen tight junctions, also demonstrated significant hypoglycemic effect [202]. 
 Interestingly this approach to drug delivery contains a mixture of some of the 
older approaches to oral delivery, colonic targeting, with some of the newest as more 
advanced delivery mechanisms are becoming necessary in order to deliver more 
advanced biological products such as larger and more complex proteins, 
oligonucleotides and whole genes [203-205].  Exciting work is being done to target 
delivery of complex therapeutics to the liver.  Methodologies include antisense and 
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ribozyme techniques, viral and non-viral vectors, prodrugs and carrier systems, such 
as liposomes, are all under investigation [206-208].   
 Another area of specificity is the targeting of drugs, especially highly 
lipophilic drugs, to the lymphatic system. The role of the lymphatic system in 
distributing large and small molecule drugs following parenteral or subcutaneous 
administration is well studied [209, 210]. In addition, the intestinal lymphatics can be 
utilized as a specialized transport and absorption pathway for highly lipohilic drugs 
offering the advantages of avoidance of the first pass hepatic effect as well as specific 
targeting of drugs to the lymphatics [211].  One application is to use glyceride 
prodrug formulations of oral anti-inflammatory agents to avoid/reduce 
gastrointestinal irritation.  Another novel indication is the ability to target anti-
infectives, immunomodulatory and anti-viral agents to the lymphatic system to 
achieve adequate oral pharmacokinetics and pharmacodynamics in the treatment of 
infectious immune diseases such as HIV [212].  
 
 
2.5.5 Carrier Systems 
 
 One of the most promising approaches to oral delivery of proteins is the use of 
carrier systems.  Systems utilizing polymer carriers, such as hydrogels, liposomes, 
nano- and microparticles and erythrocytes are all under investigation but the overall 
concept is similar.  The drug of interest is incorporated into or conjugated on to the 
carrier and administered orally.  The carrier then serves one or more of the following 
functions: to protect the protein from enzymatic degradation, to entrap the protein 
until it has reached the organ or tissue of choice, enable controlled release kinetics or 
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to improve targeted uptake and/or transport once a target tissue is reached.  The 
section that follows will provide a comprehensive review of carrier systems for oral 
protein delivery.  
 
2.6 Polymeric Delivery Systems 
 
 The concept of using a plastic as a carrier and/or depot for the delivery of 
drugs dates back to the early 1960s when silicone rubber was used as an implantable 
carrier for low molecular weight drugs and this approach continues to be an area of 
significant promise [213].  Much of the earliest work focused upon implantable 
systems, often referred to as depot systems, for prolonged sustained release.  Many of 
these early systems had the drawback of poorly controlled release and needed 
removal once therapy was complete.  Various bioabsorbable polymers made of 
hydrogels, copolymers of polylactic and polyglycolic acids, polylactic acid, 
poly(orthoesters), polyanhydrides, poly(E-caprolactone) and polyurethanes were then 
developed and studied against a wide range of drugs [214].  By the mid 1980s, 
polymeric systems were being evaluated as carriers for oral drug delivery.  These 
systems were based upon osmotic pumps, polymer-matrix slow release formulations 
and/or gastrointestinal bioadhesion [215, 216].  Since then, interest in the technology 
has blossomed, as have advances in the field of polymeric drug delivery.  The 
sections that follow will detail the history and current state of polymeric drug delivery 
with a strong focus on oral protein delivery. 
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2.6.1 Hydrogel Delivery 
 
 A hydrogel can be generically defined as a colloidal gel in which water is the 
dispersion medium.  These polymers mimic biological tissues and were first 
evaluated for use in ophthalmic products in the mid-1950s [217].  By the early 1990’s 
hydrogels were being studied as potential enablers of oral protein delivery and the 
characterization of the complexities of the relationship between hydrogel structure 
and performance was underway.  The first studies on the possible use of hydrogels for 
site specific oral protein delivery utilized novel biodegradable N-substituted (meth) 
acrylamide, N-tert-butylacrylamide and 4,4’-di(methacryloylamino)azobenzene gels.  
The gels were characterized by equilibrium swelling, elasticity in compression at 
varying pH and insulin permeability at varying pH and the degree of biodegradation 
was related to the degree of swelling [218, 219]. Further characterization determined 
that the polymer molecular weight and viscoelastic behavior of the gel has significant 
effects on the mechanisms of drug release with the lower molecular weight polymers 
displaying relatively equal rates of swelling and dissolution which resulted in a 
constant release rate of the drug etofylline [220].      
 As hydrogel characterization evolved, standard parameters were defined and 
utilized.  Figure 2.4 shows an idealized hydrogel along with key parameters.  In this 
model, Q is the volume degree of swelling, Mc is the molecular weight between 
crosslinks, ξ is the mesh size in Å, dh is the hydrodynamic radius of a drug [221, 
222].  These studies suggested that the transport of small molecular weight drugs 
from hydrogels is more impacted by the equilibrium-swelling ratio than by the degree 
of polymer crosslinking.  This work built upon previously developed mathematical 
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models of drug diffusion and release from a dissolving polymer network [223, 224].  
Soon, the concepts of bioadhesion and pH responsiveness were incorporated to 
facilitate delivery that was better controlled and more site specific [225, 226].  The 
approach of a mucoadhesive, pH-sensitive hydrogel system was then applied to the 
nasal delivery of budesonide, a seasonal rhinitis drug with low oral bioavailability 
[227].   The specific system was based upon novel copolymers of polymethacrylic 
acid and polyethylene glycol P(MAA-g-EG).  This system will be covered in detail in 
an upcoming section, as it is the core focus of this dissertation.  
 There are many other hydrogel systems that have been utilized in oral drug 
delivery, as the applications seem more endless than the list of drugs that these 
systems attempt to deliver.  The pharmacokinetics of chloroquine, a drug used to treat 
malaria, were assessed following administration via amidated pectin chloroquine 
beads suggested drug release in the duodenum, jejunum or ileum [228].  The release 
of antifungal agents, such as chlorhexidine, from chitosan hydrogels has also been 
evaluated [229].  The capabilities and behaviors of hydrogels composed of 
phospholipid polymers have been well studied.  The swelling and release of insulin 
and cytochrome c were studied in hydrogels made from 2-methacryloyloxyethyl 
phosphorylcholine copolymers and the insulin transport was found to be dependent 
upon the swelling and dissolution of the polymer chains [230, 231].  Pluronic gels 
have been evaluated for the capability to deliver Vitamin B12 nasally and polyvinyl 
alcohol hydrogels demonstrated the ability to deliver tylosin orally but not 
oxytetracycline [232, 233].   
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Hydrogel delivery systems comprised of crosslinked alginate/N,O-carboxymethyl 
chitosan have been developed and evaluated as a pH-responsive system, as have 
hydrogels utilizing natural polysaccharides and hydrogels prepared from copolymers 
of 2-hydroxyethyl methacrylate and methacrylic acid and hydrogels based on bovine 
serum albumin [234-237].  The latter system, like the P(MAA-g-EG) systems to be 
discussed later, were evaluated as a potential oral delivery system for insulin.  
Hydrogel devices such as one based upon bonded layers of a PMAA hydrogel and a 
poly(hydroxyethyl methacrylate) (PHEMA) hydrogel have been developed in order to 
provide mucoadhesion as well as unidirectional release [238].  Lastly, N-
carboxymethylchitosan-based hydrogels have been evaluated for the ability to 
provide extended release of prednisolone following oral administration [239]. 
 While all these applications have been developed there has been substantial 
work to further understand, clarify and optimize the mechanisms of action of 
hydrogels on the bench, in vitro and in vivo.  Of specific importance are GI transit 
times.  The ability of a hydrogel to remain present, and in contact, with certain tissues 
and organs can be valuable in establishing favorable pharmacokinetic profiles.  In one 
study, the gastric transit and emptying times of super-porous hydrogels (SPHs) made 
from Ac-Di-Sol((R)) (croscarmellose sodium) were evaluated in dogs.  It was 
determined that, in fasted animals, the hydrogels remained in the stomach 2-3 hours.  
When the animals were fed, the SPH remained in the stomach more than 24 hours 
[240].  A similar study in man of SPH-composite hydrogels delivered in enteric-
coated gelatin capsules demonstrated a stomach retention time of 75-150 minutes and 
that the polymers attached to the small intestine for 45-60 minutes [241].  In an 
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attempt to manipulate the mass transfer of the hydrogels through the GI tract and 
optimize protection from proteolytic enzymes, mucoadhesion strategies and 
composites of hydrogels with protective agents have also been studied [242, 243].   
Lastly, it should be noted that pH-responsive hydrogels are only one type of 
environmentally responsive gel.  Hydrogels have been engineered that are 
temperature sensitive, glucose sensitive, electrical-signal sensitive and light sensitive 
just to name a few and an excellent review of these other approaches is available 
[244]. 
 
 
2.6.2 Micro- and Nanoparticle Delivery 
 
 Colloidal oral delivery systems, such as micro- and nanoparticles are intended 
to improve pharmacokinetic and pharmacodynamic properties of drugs via improved 
mass transport mechanisms.  The very small particles are capable of delivering 
interesting diffusion profiles of their payloads, superior bioadhesion with the gastric 
mucosa and may, themselves, transfer into the blood stream, into cells or other site 
specific destinations [245-249].    
Micro and nanoparticle systems have been developed from a wide range of 
chemical approaches with the solid-lipid nanoparticle being the most common theme 
[250].  Particles have been prepared from lectins and invasions, crosslinked 
polysaccharides, polysaccharide chitosan, graft copolymers such as P(MAA-g-EG) 
and poly(D,L-lactic-co-glycolic acid), mesoporous silicon as well as natural products 
such as human serum albumin just to name a few [227, 251-257].  The design 
optimization criteria of these systems are particle size, chemical structures, surface 
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characteristics, mucoadhesion and drug-specific loading and release characteristics 
[258-261]. 
There are many applications of these colloidal delivery systems. The promise 
of targeted therapies to specific organs, tissues and cells have made them of particular 
interest in oncology where systems have been developed and studied for the delivery 
of cytoprotectives, cytotoxics and antibody therapies [262-268].  With similar hopes, 
nano-and microparticle approaches have also been developed to deliver anti-
infectives, antivirals, vaccines and antiproliferatives [269-275].  
As with most other non-parenteral protein delivery approaches, there is 
significant study ongoing for the delivery of insulin with particulate systems.  Studies 
using CaCO(3)-nanoparticles to deliver insulin transdermally in rats show promise as 
do studies applying insulin-loaded chitosan nanoparticles for nasal delivery [276, 
277].  Of course, the oral approach is preferred and there have been many attempts to 
optimize particulate systems for this purpose.  Early rat studies using insulin 
incorporated into isobutylcyanoacrylate nanoparticles showed that the insulin was 
released in the intestine but concluded that most of the protein was lost to proteolytic 
degradation in the small intestine [278].  Studies that followed have used a variety of 
nanoparticle systems including chitosan, poly(N-isopropylacrylamide) and 
poly(ethylene glycol) 400 dimethacrylate, polysaccharide chitosan (CS-NPs), 
polyethylenimine and dextran sulfate, poly(n-butyl cyanacrylate), poly-epsilon-
caprolactate and Eudragis,  polyethylene glycol (PEG)ylated trimethyl chitosan and 
gold to varying levels of success [279-284].  In the case of CS-NPs, oral 
bioavailability of almost 15% relative to sc was obtained in diabetic rats and 
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prolonged hypoglycemic effects in rats were observed with several other nanoparticle 
formulations [278, 285-288].  Clearly there is more work to be done as this approach 
is still in the pre-clinical stages. 
Lastly, it should be noted that there has been little work done to date to 
objectively study the safety of these systems.  Cytotoxicity assays can be idealized 
and the particles themselves must be studied as well as the particle-drug combination.  
Concerns have been raised regarding the long-term affects of these systems.  Some of 
these concerns parallel those related generically to polymeric drug delivery systems 
while some are specific to these colloidal particulate approaches [289, 290].  One 
such reported safety concern, the aggregation and associated long-term effects in the 
digestive tract, is one potential driver for the next approach to be discussed, 
biodegradable polymer delivery systems. 
 
 
2.6.3 Biodegradable Polymers  
 
 Carrier systems based on biodegradable polymers are of interest as the 
retention time in vivo can be designed and optimized.  Once the drug has been 
released, the polymers are broken down into inert components and eliminated from 
the body naturally.  This approach eliminates the concerns of polymer buildup in the 
body that have been previously discussed and this approach is essential when polymer 
nanoparticles are taken up by cells, tissues and organs.  Several of the carrier systems 
discussed previously are designed to be biodegradable [214, 252, 270, 275].   As is 
the case with most systems discussed so far, the polymer delivery vehicle and the 
target therapeutic must be specifically designed for each application.   
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One area of interest and application for biodegradable nanoparticles is in 
inflammatory bowel disease.  The small size, under 200 µm, enables the particles to 
avoid causing diarrhea symptoms and the particles have demonstrated the ability to be 
taken up into the macrophages and other immune-related cells that congregate at the 
sites of bowel inflammation [291].  For this purpose, Rolipram, an anti-inflammatory 
model drug, was administered to rats using poly(lactic-coglycolic acid) nanoparticles 
demonstrated fewer adverse effects than solutions.  A similar study in mice 
demonstrated reduced drug toxicity when Tacrolimus was administered via PLGA or 
pH-sensitive Eudragit nanoparticles versus oral or subcutaneous administration of the 
drug alone. 
This ability to target macrophages has also been applied to cancer therapy, 
allergy therapy/oral vaccines and in immune mediated diseases such as rheumatoid 
arthritis.  One set of experiments using PLGA nanoparticles to deliver paclitaxel in 
the HT-29 cancer cell line showed that the nanoparticles were taken up by the cells 
and that the cell mortality caused by the nanoparticle formulation was 13 times higher 
than that caused by drug alone [292].  PLGA particles have also been applied with 
some success in the oral treatment of Type I allergy [293].  Lastly, a nanoparticle 
system containing entrapped PEG-conjugated immunodominant peptides have shown 
promise in in vitro models of immune mediated and inflammatory disease [294]. 
 
2.6.4 Liposomes 
 
 Liposomes are amongst the oldest and most successful carrier systems 
for targeted drug delivery [295].  Liposomes are lipid bilayer vesicles prepared from 
mixtures of lipids that are excellent mimics of the naturally lipid bilayers of cells and  
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organelles [296].  This ‘likeness’ to cell membranes makes them very biocompatible 
and enables liposome formulations to cross cell membranes and target specific cells 
and tissues.  Liposomes can be used to encapsulate and transport drugs of diverse 
nature including hydrophilic, lipophilic and amphiphilic molecules.  This is because 
the drugs can be entrapped either within the membrane-enclosed aqueous 
compartment or bound by direct association with the lipid bilayer as shown in Figure 
2.5 [297].  Early studies for oral targeted delivery of antigens to gut-associated 
lymphoid tissue demonstrated the rapid uptake of liopsomes in the Peyer’s patches of 
the lower ileum in rats [298].   While cellular uptake can be direct and quick, 
subsequent rapid degradation of the liposome formulations in vivo can lead to short 
half-lives.   This has led to the development of stealth liposomes, which are liposome 
formulations that are modified with polyethylene glycol (PEG)–lipid derivatives.  The 
bulky PEG group prolongs the liposome life by inhibiting uptake into the 
reticuloendothelial system [299].  This approach has led to the successful approval 
and marketing of injectable liposome formulations in oncology, doxorubicin and 
daunorubicin and in anti-fungals, amphotericin [300].     
 Liposomes have been evaluated as carrier systems for insulin.  Early studies 
demonstrated the ability of liposomal insulin to target hepatocytes when administered 
intravenously but the oral liposomal formulations resulted in an unacceptable amount 
of variability in the glycemic response [301].  To improve bioavailability, the coating 
strategy discussed above has been employed using PEG-2000 and mucin coatings.  
Aimed at prolonging intestinal transit times, the study showed that the mucin-coated 
liposomes had a longer gastric retention time but intestinal transport was unaffected.  
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However, the PEG-2000 coated liposomal formulation was retained in the small 
intestine much longer via interaction with the mucous layer [302].  Chitosan coating 
has also been used to improve the hypoglycemic efficiency of oral insulin delivered 
via liposomes in mice [303].  Similarly lectin-modified insulin liposomes have shown 
promise as a relative bioavailability of 9.12% when compared to subcutaeneous 
insulin has been achieved [304].   While these results are promising, there is a 
significant gap that must be bridged as oral absolute bioavailability of 10% or greater 
is required for serious commercial interest. 
 
 
2.6.5 Micelles 
 
 Micelles are another class of nanoparticle structures that are of specific 
interest in advanced drug delivery.  Like liposomes and lipid bilayers, micelles can be 
generically defined as amphipathic lipid aggregates that naturally form in water as 
shown in Figure 2.6 [11].  Micelle-like structures can be formed using block 
copolymers, which enable the utility of combining the desired aspects of more than 
one homopolymer [305].  Micelles can self-assemble from block copolymers, which 
have hydrophilic and hydrophobic segments as shown in Figure 6.    
 The small size, typically 10-100 nm, of micelles and the hydrophilic outer 
core offer the drug entrapment possibilities of liposomes but without significant risk 
of premature dissolution by the reticuloendothelial system (MPS).  Further the in vivo 
stability of micelle-drug formulations is strongly related to the physical state of the 
core-forming polymer with micelles having a glass transition temperature (Tg) of  
 54
greater than 370C being considered very stable [306].  Drug can be released from 
micelles either through partitioning or via disintegration of the micelles.  Preliminary 
studies confirmed the pH-responsiveness and the ability to release progesterone in an 
in vitro model [309].  Micelle systems based upon poly(hexyl- 
substituted lactides), poly(lactide)-poly(ethylene glycol), DEX-g-PEO-C16 and self-
assembling PEG-p(CL-co-TMC) copolymers have all been studied as potential carrier 
systems for hydrophobic drugs [310-313].  Lastly, there is little available information 
to support that much effort has been applied towards the delivery of insulin via 
micelles.   
 
2.6.6 Mucoadhesion 
 
 As the above oral polymeric carrier systems have been discussed, it was 
apparent that many of the systems were designed to optimize the corresponding 
mucoadhesive properties.  The purpose of mucoadhesion is twofold.  First, it is 
assumed that mucoadhesive delivery systems can improve pharamcokinetics by 
ensuring intimate and prolonged contact with the designated tissues in the 
gastrointestinal system.  Second, this prolonged contact should reduce the loss of drug 
via fecal elimination, as the carrier should stick to the gut walls once contact is made.  
The mass transfer situation of flow in the gastrointestinal tract has been modeled via 
the cases of peristaltic transport in a channel with a porous peripheral layer and as 
nonideal chemical reactors [314, 315].  The resulting mathematical models were 
complex as the movement of a core volume; a porous and static boundary layer, fluid 
trapping, axial mixing and reflux were all significant variables.  A simplified model is 
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presented in Figure 2.7, which shows a laminar flow situation where the probability 
of wall contact of suspended particles is extremely complex. 
Efforts to improve the mucoahesive, or bioadhesive, properties of a given 
carrier system are, obviously, fairly specific to the polymer chemistry of the carrier 
system itself.  Early work on controlled release tablets made of hydroxypropyl 
methylcellulose and poly (acrylic acid) demonstrated that the adhesion strength 
between the tablets and bovine gut mucosa was a monotonically increasing function 
of the poly (acrylic acid) content [316].  Soon after, the cationic charged chitosans 
were demonstrated to improve intestinal transport in in situ models due to its adhesive 
properties and the ability to bind to lectins on the walls of the GI tract [317].  It has 
often been the case that adhesion enhancers were combined in models with protease 
inhibitors in order to reduce the enzymatic degradation of the drug payload.  This has 
led to the desire to develop a system that could inhibit a membrane-bound protease, 
even when the enzyme was protected by a mucous layer, by displaying a high binding 
affinity to bivalent cations [318].   
 More recent work still focuses on lectin binding as well as non-specific 
glycocalyx adhesion and virtually all polymeric carrier systems have mucoadhesion 
designed into the chemistry [242, 319].  One recent example in oral insulin delivery 
utilized a lectin wheat germ agglutinin (WGA) conjugated to alginate microparticle 
system in rats.  It was determined that the WGA-alginate particles showed the most 
pronounced hypoglycemic effects but it was unclear if this effect was caused by 
prolonged residence time from mucoadhesion [320].   Hence, it is clear that 
theoretically and experimentally the concept of mucoadhesion is an important design 
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criteria for polymeric oral drug delivery systems.   That said, the previously stated 
cautions regarding toxicity and potential buildup of polymer in the digestive tract 
long-term will need to be carefully evaluated in order to ensure regulatory approval of 
such systems. 
 
2.6.7 Bioconjugation 
 
 Bioconjugation is defined as the linking of two or more molecules to form a 
novel complex having the combined properties of the individual components [321].  
This can be illustrated as the chemical modification of a protein with a polymeric 
carrier.  Many examples of this chemical approach have been given in earlier sections 
such as the conjugation of a protease inhibitor to a polymeric carrier to protect a 
protein drug from proteolytic breakdown.  In addition to these examples, 
bioconjugation itself can be a protein drug delivery strategy.  By covalently bonding a 
polymer to a therapeutic protein, enzymatic degradation can be reduced as the 
polymer can act as a protective shield.   Furthermore, polymer conjugation may 
improve pharmacokinetics by increasing the molecular weight of small proteins past 
the kidney elimination threshold [322].  Recently, promising results were obtained 
using bioconjugation of a water soluble polymeric carrier (poly(vinylpyrrolidone-co-
dimethyl maleic anhydride)) to bioactive cytokines for use in targeted cancer 
therapeutics.  In this case the relative potency of the drugs was increased [323]. 
  
 
2.7 Oral Insulin Delivery 
 
 As stated earlier, the incidence and costs of diabetes treatment for insulin-
dependent diabetes is staggering [13].  In addition to the social, behavioral and 
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economic justifications for oral insulin delivery, there are physiological reasons.  As 
parenteral insulin administration targets peripheral tissues, rather than the liver, the 
normal dynamics of insulin release are not replicated [324].  This causes a delay in 
the onset of action as well as the need for higher insulin dosing.  When this concept is 
combined with the many justifications previously stated, the reasons why we have 
seen insulin used as a model drug in almost every oral protein delivery system and 
methodology are apparent.  In addition to being a model drug for varied drug delivery 
methodologies, there have been many approaches designed specifically for oral 
insulin delivery.  Several of these approaches are described below. 
 Back in 1986, targeted colonic delivery in rats was attempted by coating 
insulin with polymers that were cross-linked with azoaromatic groups to form a 
protective shield [325].  There have also been numerous attempts to improve enteral 
insulin pharmacokinetics by novel formulation.  Promising hypoglycemic results 
compared to controls were observed in rats when insulin was delivered via soft 
gelatin capsules coated with the polyacrylic polymer, Eudragit and containing a 
mixture of surfactants [326].  Another novel approach was to use lipoidal dispersion 
of insulin in fatty acids.  A reduction of blood glucose from 105 mg/dl to 75 mg/dl in 
30 minutes was observed in rabbits when a palmitic acid system containing 5 U 
insulin/50 mg dispersion was administered orally [327].  Similary, water-in-oil-in-
water (W/O/W) insulin emulsions containing lipoidal enhancers have been evaluated 
in animal models and it was determined that the biological efficacy of the emulsion 
was largely dependent on the lipid that constituted the oily phase [328].  Another 
formulation approach was to deliver insulin in a solid formulation consisting of 
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insulin mixed with cholate and soybean trypsin inhibitor.  This approach 
demonstrated decreased blood glucose levels in dogs of greater than 20% of the initial 
value with the peak effect occurring after 60-140 minutes and lasting for more than 
90 minutes [329].  Thiolated chitosan-insulin formulations of tablets and 
nanoparticles have also been studied in rats.  In the case of the chitosan tablets given 
to non-diabetic rats, decreasing glucose levels were observed for 24 hours and in the 
case of chitosan-insulin nanoparticles, prolonged hypoglycemic effects of up to 
eleven hours were observed [287, 330].    
 
2.7.1 Carrier systems for Insulin 
 
 As we have seen there are many carrier systems developed for oral protein 
delivery and most have employed insulin as a model drug.  In summary, carrier 
systems for oral insulin delivery have included polymeric delivery systems, such as 
hydrogels, micro- and nanparticles, biodegradable polymers, liposomes and micelles, 
mucuadhesive polymers and bioconjugated polymer-protein formulations.  Within 
each of these subsets, varying polymer chemistries have been applied.  In addition, 
many of these systems have undergone optimization attempts via the incorporation of 
protease inhibitors or via efforts to increase mucoadhesion. 
 There are several additional cases of targeted insulin delivery systems that 
have not yet been discussed.  Several insulin derivates using polyethylene glycol 
(PEG) have been investigated.  In the case of calcium phosphate-PEG-insulin-casein 
(CAPIC) particles, hypoglycemic effects of 50% of control were seen over the first 3 
hours post dosing in diabetic mice [331].  Similarly, another PEGylated insulin 
approach utilized insulin-monomethoxypoly(ethylene glycol) derivates prepared by 
 59
the preparation of mono- and di-terbutyl carbonate insulin derivatives demonstrated a 
40% reduction in blood glucose within 3 hours of treatment [332].   
 Lastly, an additional novel approach is the use of an intestinal patch for 
enteral delivery.  The concept is to concentrate insulin into a mucoadhesive patch that 
attaches to the intestinal mucosa allowing the patch to concentrate insulin locally for 
better absorption while still protecting the drug from enzymatic degradation.  In one 
study, patches were prepared from Carbopol 934, pectin and carboxymethylcellulose 
at a weight ratio of 1:1:2.  While a significant hypoglycemic effect was observed in 
rats in situ, the ability of the patches to remain attached to the intestinal wall 
decreased with increasing fluid volume in the intestines [333].  I feel that if adequate 
adhesion profiles are obtained with this type of approach and if one-directional 
insulin diffusion from the patches can be achieved, this approach could be very 
promising.   
 
2.7.2 P(MAA-g-EG) Hydrogels 
 
 The focus of this lab over the last two decades has been on a novel pH-
sensitive complexation hydrogel system.  As previously defined, hydrogels are water-
swollen, crosslinked polymeric structures produced by the reaction of polymeric 
monomers or by association bonding [334].  The chemical and physical cross-links 
provide the network structure and physical integrity of the hydrogel while also 
rendering them insoluble.  They are rubbery, can swell in the presence of some 
biological fluids and are highly biocompatible.  These properties allow hydrogels to 
resemble living tissues more closely than any other class of synthetic biomaterials 
[335].  Although useful in many applications, such as contact lenses and dental 
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materials, it as a carrier system for protein drugs that is the focus of this current work.  
Specifically, a P(MAA-g-EG) hydrogel system will be detailed through the rest of 
this section. 
 
2.7.2.1 Hydrogel Theory 
 
 Before the P(MAA-g-EG) system can be discussed, a brief overview of 
hydrogel parameters should be understood.  The network permeability and swelling 
behaviors of a hydrogel network are important characteristics in the evaluation of a 
polymeric gel as a controlled release system.  These aspects are mostly determined by 
the chemical nature of a polymer.  As you may recall, an idealized hydrogel was 
presented in Figure 4 with Mc defined as the molecular weight of the polymer chains 
between cross-links and ξ defined as the network mesh size, which is a measure of 
porosity literally defined as the distance between consecutive cross-links.  The 
polymer volume fraction v2s is another important parameter and is defined as the 
polymer volume fraction in the swollen state.  Mathematically, v2s can be defined as 
the ratio of the volume of the polymer (Vp) to the volume of the swollen gel (Vgel) as 
shown in equation 2.10. 
v2s = Vp / Vgel =1/Q    (2.10) 
Here Q is defined as the polymer fraction of polymer in the gel, which is a measure of 
how much fluid the hydrogel can incorporate into its structure when completely 
swollen.  This quantity can be obtained experimentally from equilibrium swelling 
experiments.  The degree of cross-linking in a hydrogel, X, is defined as the ratio of 
the molecular weight of the repeating units making up the polymer chains, Mo, to the 
molecular weights of the polymer chains between cross-links as shown below. 
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X = Mo / 2Mc   (2.11) 
The ability of a hydrogel to swell and contain a fluid enables the hydrogels to take up, 
hold and release drugs.  This essential property is enabled by ionic hydrogels.  These 
hydrogels contain pendent groups that are cationic or anionic in nature.  For anionic 
gels, such as the P(MAA-g-EG) system, the side groups are unionized below the pKa 
and the swelling is governed by the thermodynamic compatibility of the polymer and 
swelling agent.  Above the pKa however, the pendent groups are ionized and the gels 
swell substantially due to the creation of a large osmotic swelling force created by 
higher concentration of ions present as shown in Figure 2.8.  The opposite is true for 
cationic hydrogels.  The relationship of the hydrodynamic radius, dH, of a specific 
drug to the network pore size, ξ, is an essential design parameter was presented earlier 
in Figure 2.4.  Significant work has been done by Peppas et al to understand the 
detailed correlations between mesh size and the equilibrium degree of swelling of 
polymeric networks [336].  Lastly, the equations for diffusion of a drug from a 
macroporous hydrogel can be defined in terms of an effective diffusion coefficient, 
Deff and the partition coefficient, Kp, as in Eqn 2.9 where Diw is the diffusion 
coefficient of the solute in the pure solvent, ε is the network porosity and the network 
tortuosity is τ.    
    Deff = Diw (Kp ε / τ)  (2.12) 
 
2.7.2.2 Synthesis and Properties of P(MAA-g-EG) Hydrogels 
 
Through the work of Lowman, Peppas et al the methods to synthesize 
P(MAA-g-EG) hydrogels has been optimized from the earliest published methods 
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[337].  For the sake of this dissertation, the following approach has been utilized.  
Microparticles of P(MAA-g-EG) are prepared via free-radical solution photo-
polymerization of methacrylic acid, MAA, and poly(ethylene glycol) methacrylate, 
PEGMA.  The monomers are mixed in appropriate molar ratios to yield a 1:1 ratio of 
MAA:EG units in the resulting hydrogel.  The monomers are then diluted to a desired 
(wt./wt.) of the total monomers with a 1:1 (vol./vol.) mixture of ethanol and water.  
Tetraethylene glycol dimethacrylate, TEGDMA, is then added as a cross-linking 
agent at X = 0.075 moles TEGDMA per MAA.  DMPA was added as the initiator in 
the amount of 1% weight of the monomers. 
The resulting reaction mixtures are then formed into films by insertion into a 
glass mold that allowed for formation of a polymer film with a thickness of 0.8 µm.  
The reactions are initiated and run to completion by exposing the monomer film to 
UV light (Ultracure 100, Efos, Buffalo, NY) at 1 mW/cm2 at 365 nm for 30 minutes.  
The hydrogel films can then be removed from the molds and rinsed for 1 week in 
distilled H2O (changed daily) to remove the un-reacted monomers and sol fraction 
[338].  The generic synthetic pathway is shown in Figure 2.9 below. 
 
 
2.7.2.3 The in vitro and in vivo Characterization of P(MAA-g-EG) Hydrogels for 
Oral Insulin delivery 
 
The in vitro characterization of this novel hydrogel system can be broken 
down into two domains; the physical characterization of the polymer itself and the 
characterization of the biological activity of the polymer in in vitro and in situ 
biological models.  A chronological progression of the progress of the in vitro 
characterization of this novel complexation hydrogel system follows. 
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As previously stated, the abilities of a hydrogel carrier system to take up, 
carry and release drug are key design criteria.  In the case of the P(MAA-g-EG) 
system, extensive work has been done.  The earliest efforts involved loading hydrogel 
particles with porcine insulin.  The technique was to simply soak hydrogel particles in 
an insulin solution at pH 7.4 for 24 hours.  It was determined that approximately 95% 
of the insulin in the solution was entrapped within the polymer.  After drying and 
final processing, the particles were loaded into gel capsules and administered orally to 
male Wistar rats in which diabetes had been induced by injection of streptozotocin 
several weeks earlier.   This study demonstrated an absolute oral bioavailability of 
~4% in healthy rats that had been dosed orally at 50 IU/kg [339].   It was also 
determined that the hypoglycemic effects were dose related. 
Later that same year, the mucoadhesive and drug uptake and release properties 
of the P(MAA-g-EG) system was studied.  Using drugs of various sizes, it was 
determined that the diffusion of a protein drug through a swollen polymer was 
significantly hindered by the presence of cross-links as well as other physical 
obstructions in the polymer network.  The mucoadhesive behavior of the gels was 
studied as a function of force and displacement for gels at different pH values.  It was 
determined that the adhesive force was significantly higher at higher pH indicating 
that the free PEG chains may be serving as anchors to mucin under those conditions.  
Lastly the fractional release of insulin over time was documented for PEG chains of 
molecular weight 1000 in buffered saline solutions following dissolution in simulated 
gastric fluid for several hours demonstrated the expected gastric protection [337]. 
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A similar pH-sensitive glycopolymer system developed by free-radical 
polymerization of methacrylic acid and 2-methacryloxyethyl glucoside, using 
tetra(ethylene glycol) dimethacrylate as a cross-linking agent was physically 
evaluated in detail.  The swelling behavior was studied as a function of pH and 
copolymer composition.  It was determined that the transition between the swollen 
and collapsed states occurred at pH 5 and that the mesh sizes of the hydrogels were 
18-35 Å in the collapsed state (pH 2.2) and were between 70 and 111Å at pH 7 in the 
swollen state [340].  It was also determined that the swelling ratio of the polymers 
decreased as the cross-linking ratio of the copolymers increased. 
The physiochemical behavior and potential cytotoxicity of a nanosphere 
presentation of the P(MAA-g-EG) system was then evaluated in detail.  Cytotoxicity 
was determined using an indirect measurement via a colorimetric assay and directly 
via a trypan blue exclusion method.  The colorimetric assay demonstrated that Caco-2 
cell monolayers remained more than 95% viable relative to controls.  The cell 
counting method produced less precise and predictable variables due to cell 
separation and other complexities of that method.  Transepithelial electrical resistance 
measurements (TEER) of the cell monolayers demonstrated that contact with the 
hydrogels did disrupt the cell monolayer.  It was theorized that this was due to the 
opening of tight junctions by the chelation capabilities of these gels.  The effect was 
found to be related to the amount of methacrylic acid in the hydrogels and was 
reversible [341].  The resulting conclusion of this study was that this complexation 
hydrogel system had the ability to enhance enteral insulin absorption via the 
paracellular route due to this ability to reversibly open tight junctions.  Similar results 
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were obtained by Foss in 2004 using a P(MAA-g-PEG) hydrogel system [342].  In 
this paper, a correlation between decreasing TEER values and increasing insulin 
transport was determined to indicate paracellular transport.  It was also shown that the 
hydrogels had a negligible effect on NADPH production by the cells, an indication of 
low or negligible toxicity. In addition, the relationship on monomer feed ratios was 
studied and it was determined that ratios of 1:1 and 2:1 were optimal when compared 
to monomer feed ratios of 3:1 and 4:1. That said, with respect to the mechanism of 
insulin transport, as the Caco-2 cells do have the insulin receptor, transcellular 
transport cannot be ruled out as a contributor. 
In a similar Caco-2 study, microgels composed of cross-linked copolymers of 
Poly(acrylic acid) and Pluronics were evaluated as permeation enhancers for 
doxyrubicin.  It was shown that the microgels inhibited P-gp-mediated doxyrubicin 
efflux and enhanced the passive influx.  In this case it was determined that no 
meaningful enhancement of paracellular transport was observed [343].   
In 2003, the next body of work on the P(MAA-g-EG) system involved study 
of the in vitro release behavior and the stability of insulin within the delivery system.  
A rapid release of insulin from the polymer was observed at pH 6.5 when the pH was 
titrated up from pH 2.2.  It was also shown that the biological activity of insulin 
decreased as the molecular weight of the PEG component was increased.  Lastly, 
PEG chains of molecular weight 200 demonstrated the best protective and release 
kinetics [344].   
The influence of the reaction solvent content was studied in detail in late 
2003.  The effects of network morphology on the insulin delivery characteristics of 
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the system were also investigated.  By preparing gels with greater reaction solvent 
contents, it was shown that the polymer mesh size was an increasing function of 
solvent content [338].  Similarly it was demonstrated that gels prepared with higher 
solvent content were capable of swelling to a greater degree.  The pH-based 
protective capabilities were confirmed once again and insulin release rates were also 
increased with the solvent content of the reaction mixture.  Closed loop rat studies 
showed that the insulin relative bioavailabilities were also a weak function of reaction 
solvent content, ranging from 4.6% for a polymer with a solvent fraction of 66.3% to 
7.2% bioavailability for polymer with a solvent fraction of 22.3%.   
The effects of the molecular weight of the PEG chains in the P(MAA-g-EG) 
hydrogel system and the effects of microparticle size on TEER and insulin transport 
in caco-2 cells have also been studied [345].  It was determined that TEER values 
were not a function of PEG molecular weights but that decreased microparticle sizes 
and shorter PEG chain lengths did lead to higher insulin permeability values in the 
Caco-2 model.  This influence of sub-chain molecular weights was also studied by 
Ostroha et al [346].  In this study it was determined that the maximal degree of 
hydrogel swelling did increase weakly with sub-chain molecular weight.  It was also 
determined that salt concentration has a significant effect on swelling at pH ranges 
near the transition value.  This is an important event as it is the first documented 
detail on the effects of osmolarity on this delivery system.  Lastly, it was shown that 
the incorporation of water-soluble uncharged pendant chains can increase the driving 
force for swelling without affecting the sub-chain elastic restoring force.  Similar 
work on the effects that varying PEG molecular weights have on swelling and release 
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were presented by Peppas.  In this work, the effects of PEG chain molecular weight 
on mucoadhesion was also studied using a tensile tester approach.  It was determined 
again that the polymer is more mucoadhesive at high pH ranges due to the ability of 
free PEG chains to serve as anchors to mucin under these conditions [347]. 
The effects of particle size on the enteral absorption of insulin was detailed by 
Morishita et al [348].  Using an in situ closed loop procedure in rats, the hypothesis 
that smaller ILP particles would provide better insulin transport via improved 
mucoadhesion was confirmed with particles of not greater than 43 µm in diameter 
showing the most pronounced hypoglycemic effects.  It was also shown that the 
greatest effect was obtained when the particles were placed in the ileal segment when 
compared with analogous dosing in the jejunum.  Lastly, it should be noted that much 
of the above work up to this time has been documented in an excellent review article 
by Peppas et al [349]. 
The most recent work on the P(MAA-g-EG) hydrogel system has focused on 
using animal models to determine the absolute and relative bioavailability of insulin 
delivered from the system.  As previously discussed, most of the earlier work in 
animals have been in situ studies, which necessitate the introduction of many non-
ideal variables such as deep anesthesia, significant handling stress, prolonged fasting, 
and bypass of the upper GI system just to name a few.  Well-designed animal studies 
can remove or reduce the effects of most of these variables.  In a recent publication, it 
was demonstrated that insulin-loaded polymer microparticles (ILP) with diameters < 
53 µm composed of a 1:1 molar ratio of MAA:EG units demonstrated a relative 
bioavailability of 9.5% when compared to subcutaneous insulin injection in healthy 
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rats.  The associated pharmacodynamic study demonstrated the ability of the ILP 
system to suppress post-prandial glucose elevations in a multiple dose study [350].  
While these results are promising, the fact that the animals were fasted extensively 
prior to the study raises some concerns.  As previously discussed in an earlier section, 
the biochemical makeup of the intestinal brush border and intestinal motility vary 
significantly with changes in feeding times.  It can be assumed that this study was 
conducted under fairly non-physiological conditions.  
  
 
2.7.2.4 The in vitro and in vivo Characterization of P(MAA-g-EG) Hydrogels for 
Oral delivery of other drugs and other routes of administration 
 
Early work with this complexation hydrogel system evaluated the potential for 
the delivery of protein therapeutics other than insulin and by routes other than oral.  
In a paper by Makamura et al, the nasal delivery of budesonide, a derivative of 
predonisolone used for the treatment of asthma and seasonal rhinitis, was evaluated 
using the P(MAA-g-EG) hydrogels system as the protein carrier [227].  This drug has 
been previously demonstrated to have a low oral bioavailability of ~11%.  Using 
hydrogel microparticles to deliver the protein nasally in rabbits, a bioavailability of 
~84% was reported.  More recently, a nanoparticle formulation of this system was 
evaluated in several in vitro transport and tumor models for its possible efficacy in 
delivering chemotherapeutic agents [351].  It was demonstrated that the polymer 
nanoparticles enhanced bleomycin transport across Caco-2 cell monolayers and that 
drug released from the nanospheres successfully induced DNA damage in the DLD-1 
tumor model. 
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2.7.3   Oral Insulin Clinical Trial Results  
 
 As of August 2006, a search for oral insulin on the clinicaltrials.gov website 
returns 55 studies that are currently recruiting patients.   For the most part, these 
studies are targeting Type II diabetic patients using various oral anti-diabetic agents.  
There are also several trials ongoing for the inhalant spray insulin formulations.  It is 
startling, and somewhat disappointing, that, despite the hundreds of oral insulin 
approaches cited in this chapter, virtually none have made it to the clinic.  There has 
been some successes however and this chapter will focus on the most recent, and 
promising, oral insulin clinical trial results. 
Hexyl-insulin monoconjugate 2 (HIM2) is an orally active insulin that is 
created by a site-specific oligomeric modification of recombinant human insulin 
[352].  An oligomer comprised of a PEG moiety plus an alkyl linker, is attached to 
B29 lysine.  This formulation offers longer half-life, greater resistance to proteolytic 
damage and greater solubility in water and lipid-based media.  In an open-label, non-
randomized phase I/II clinical trial, 14 patients showed significant hypoglycemic 
effects from oral administration of this insulin formulation when added to a basal 
insulin regimen.  In addition, no detectable adverse safety signals were observed.  The 
utility of this formulation will most likely be tested next to evaluate the blood glucose 
control efficacy in the absence of basal subcutaneous insulin. 
Another recent study compared the PK and PD of a single-dose oral insulin 
spray with subcutaneous insulin.  In this small study using six healthy male 
volunteers, the oral spray demonstrated a higher CMAX and shorter TMAX than 
subcutaneous insulin, as well as faster time to peak glucose uptake [353].  These 
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PK/PD results imply that this formulation may be helpful in managing meal-related 
blood sugar excursions.  It must also be noted that four of the six subjects complained 
of a strange sensation and taste in their mouths and 3 subjects experienced mild 
dizziness.  That said, all of the effects were of short duration and the vital signs of all 
patients remained stable throughout this study. 
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Figure 2.1: The Oral Delivery Gauntlet 
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Figure 2.2: Routes of Drug Transport Across Cellular Barriers (A) Passive 
Transcellular;    (B) Passive Paracellular; (C and F) Carrier-mediated Uptake; 
(D and E) Carrier Mediated Efflux 
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Figure 2.3:  Tight Junction Structure 
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Figure 2.4:  Key Hydrogel Parameters Mc is the molecular weight between 
crosslinks, ξ is the mesh size in Å, dh is the hydrodynamic radius of a drug 
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Figure 2.5: Lipid Formulations 
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Figure 2.6:  Amphipathic Lipid Aggregates that Naturally Form in Water 
 
 
 
 
 
 
 
 77
 
 
 
Figure 2.7:  Schematic of Flow through the GI tract 
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Figure 2.8: Swelling of an Anionic Hydrogel 
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Figure 2.9: P(MAA-g-EG) Hydrogel Synthesis 
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CHAPTER 3: RESEARCH GOALS 
 
 
The ultimate goal of this work is to support the development of an oral drug 
delivery system for protein therapeutics based upon complexation hydrogel 
technology by gaining a detailed understanding of its mechanisms of action.  A novel 
pH-sensitive poly [methacrylic acid-grafted-poly (ethylene glycol)] hydrogel system 
has previously demonstrated enhanced insulin bioavailability in an in vivo model.  
The strategy of the current work included characterization of the in vitro transport 
enhancing effects of this system followed by a solid pre-clinical evaluation of the 
system.  The approach can be parsed into 4 specific aims. 
 
Aim #1:  Select, develop and establish an in vitro model of gastrointestinal transport.  
Various models of gastrointestinal transport were studied.  The Caco-2 cell line was 
selected as the optimal model of gastrointestinal transport.  The cells were purchased 
and a viable culture line was established. 
 
Aim #2:  Establish transepithelial resistance measurement capability as a model of 
monitoring confluence of cellular cultures and tight junction integrity.  Models of cell 
monitoring were studied and transepithelial electrical resistance monitoring (TEER) 
was selected and implemented.  TEER monitoring was used to evaluate the 
performance of the cell cultures as well as to determine confluency. 
 
Aim #3:  Confirm the ability of hydrogel to protect insulin in the upper GI system, 
the ability to release insulin in the lower GI system via dissolution studies and 
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quantify the insulin transport capability of the hydrogel system via permeability 
studies.  The ability of hydrogel to protect insulin in the upper GI system and the 
ability to release insulin in the lower GI system was demonstrated via dissolution 
studies in the USP models simulated gastric fluids containing active enzymes.  The 
insulin transport capability of the hydrogel system was quantified via permeability 
studies 
 
Aim #4:  Develop a detailed pre-clinical profile of hydrogel system including proof 
of concept, dosing, toxicity and pharmacokinetic and pharmacodynamic profiling via 
an in vivo study.  An in vivo pre-clinical evaluation of the hydrogel system in two 
species was utilized to determine the absolute bioavailability of insulin delivered 
orally via this system.  These studies utilized an advanced intravenous-to-oral 
crossover design to enable the most accurate model of oral dosing obtained to date on 
this hydrogel system.  Lastly, the pharmacokinetic and pharmacodynamic properties 
of insulin delivered via the P(MAA-g-EG) hydrogel system were detailed via 
pharmacokinetic modeling. 
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CHAPTER 4: SYNTHESIS AND CHARACTERIZATION OF P(MAA-G-EG) 
HYDROGELS 
 
 
4.1 Introduction 
 
 As previously discussed, hydrogels have been a focus of study in drug 
delivery and biomaterials applications for several decades.  The particular focus in 
this lab has been the development of a novel pH-sensitive complexation hydrogel 
system.  Significant strides have been made in hydrogel theory, practical synthesis 
and the physical and in vitro characterization of hydrogels. 
 Hydrogels were defined in the early 1940s as water-swollen, cross-linked 
polymeric structures produced by the reaction of one or more monomers or by 
association bonding such as hydrogen bonding and/or van der Waals interactions of 
the polymer chains 1,2.  Hydrogels can be classified in many ways by charge (neutral, 
anionic, cationic and ampholytic), by mechanical and structural properties (affline, 
phantom), by method of preparation (homopolymer networks, copolymer networks, 
multipolymer networks or interpenetrating polymer networks) or, lastly, by physical 
structural features (amorphous, semicrystalline, hydrogen-bonded, supermolecular 
network structures or hydrocolloidal aggregates)1.   The key parameters that 
distinguish hydrogels physically and behaviorally have become much more 
understood.   
Of particular importance is the relationship between the hydrogel mesh size 
(ξ) and the degree of swelling within a polymer network.  These parameters directly 
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influence the transport mechanisms of drugs and other molecules through the polymer 
networks.  For example, it is known that the diffusion coefficient of a drug through a 
hydrogel decreases as the crosslinking density increases3.   Similarly, it is known that 
the polymer molecular weight directly affects the drug release behaviors from 
hydrogel networks 4.  Quantitatively, hydrogel structure and behavior can be 
characterized by several key relationships.  The polymer volume fraction (v2s) is the 
ratio of the polymer volume (Vp) to the volume of the swollen gel (Vgel) and is 
defined by equation 2.10. 
v2s = Vp / Vgel = 1/Q     (2.10) 
where Q is defined as the polymer fraction of polymer in the gel, which is a measure 
of how much fluid the hydrogel can incorporate when swollen to its maximum state.  
This parameter can be obtained experimentally from equilibrium swelling 
experiments.  The degree of crosslinking in a gel (X) is defined by equation 2.11 
  X = Mo / Mc      (2.11) 
Where Mc is the molecular weight of the polymer chains between crosslinks and Mo is 
the molecular weights of the polymer units that make up the polymer chains5.  The 
network pore size can be obtained from equation 4.1 where r02 is defined as the 
unperturbed end-to-end distance of the polymer chains between cross-linking points  
  ξ = α(r02)1/2       (4.1) 
and the elongation (α) can be related to the swollen polymer volume fraction, 
assuming isotropic swelling.  
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 The swelling and release behaviors of hydrogels are also critical parameters.  
In the case of ionic hydrogels, swelling behavior can be described in terms of the free 
energy (∆G) of the system as shown in equation 4.2. 
 ∆G = ∆Gmix + ∆Ggel + ∆Gelastic + ∆G ion  (4.2) 
Which presents the system free energy as a summation of free energy of mixing, 
elasticity and ionic potential.  In macroporous hydrogels, gels with pore sizes between 
0.1 µm and 1 µm, diffusion can be characterized in terms of the diffusion coefficient 
of the solute in pure solvent, as well as the network porosity and tortuosity as shown 
in equation 2.12. 
  Deff = Diw (Kp ε / τ)     (2.12) 
Lastly, many of these parameters can be obtained experimentally, either by direct 
measurement or by application of some of the above relationships.  Specifically, the 
diffusion coefficient can be obtained via membrane permeation, 
absorption/desorption studies, scanning electron microscopy (SEM), infrared 
spectroscopy (IR) or quasi-elastic light scattering (QELS) and methods information of 
each of these approaches is readily available 6. 
In the current work, hydrogels were synthesized by free-radical solution 
photo-polymerization.  In photo-initiated reactions, polymerization occurs when 
radicals are produced by UV and/or visible light.  This can happen when a compound 
in the reaction undergoes excitation via energy absorption and decomposes into 
radicals or when the excited species interacts with a second compound to form 
radicals of one species via energy transfer or redox 7.  Crosslinking to form the 
hydrogel network occurs when the branches from the growing polymer chains 
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interact with one another.  The polymer growth is eventually terminated by the 
destruction of the reactive center by an appropriate reaction.   
In order to understand the potential for a hydrogel system to act as a protein 
drug carrier, detailed characterization is required.  As previously mentioned, the 
volume swelling (Q) and the weight swelling ratio (q) can be obtained 
experimentally.  Similarly, the hydrogel network structure and the loading and release 
kinetics of a given hydrogel system can be obtained using in vitro techniques 8. 
In the current work, P(MAA-g_EG) hydrogels were synthesized and 
physically characterized in preparation for detailed in vitro and in vivo 
pharmacokinetic and pharmacodynamic study. 
 
4.2 Experimental Section 
4.2.1 Materials 
 Methacrylic acid (MAA), pepsin, pancreatin and insulin (bovine and human) 
were purchased from Sigma Aldrich (St. Louis, MO).  Dimethoxy propyl 
acetophenone (DMPA) was purchased from Aldrich (Milwaukee, WI).  The MAA 
was purified via packed column of DE-HIBIT 200 (Polysciences, Warrington, PA) in 
order to remove the inhibitor (hydroquinone monomethyl ether).  Methoxy-
terminated poly(ethylene glycol) monomethacrylate 1000 (PEGMA), and 
tetraethylene glycol dimethacrylate (TEGDMA) were all purchased from 
Polysciences (Warrington, PA).  All chemicals were used as supplied unless noted as 
exceptions below. 
 
 116
 
 
4.2.2 Preparation of P(MAA-g-EG) Hydrogels 
 Microparticles of P(MAA-g-EG) were prepared via free-radical solution 
photo-polymerization of MAA and PEGMA 8.  The monomers were mixed in 
appropriate molar ratios to yield a 1:1 ratio of MAA:EG units in the resulting 
hydrogel.  The monomers were then diluted to 44.7% (wt./wt.) of the total monomers 
with a 1:1 (vol./vol.) mixture of ethanol and water.  TEGDMA was added as a cross-
linking agent at X = 0.075 moles TEGDMA per MAA.  DMPA was added as the 
initiator in the amount of 1% weight of the monomers. 
 The reaction mixtures were pipetted into a glass mold that allowed for 
formation of a polymer film with a thickness of 0.8 µm.  The reactions were initiated 
and run to completion by exposing the monomer film to UV light (Ultracure 100, 
Efos, Buffalo, NY) at 1 mW/cm2 at 365 nm for 30 minutes.  The hydrogel films were 
removed from the molds, rinsed for 1 week in distilled H2O (changed daily) to 
remove the un-reacted monomers and sol fraction. 
 
4.2.3 Insulin Loading 
 Hydrogel films were dried under vacuum at 37ºC and then pulverized into fine 
particles using a mill (Bell Art Products, Pequannock, NJ).  The particles were further 
ground using a mortar and pestle and passed through sieves with a particle size cutoff 
of 43 µm.  An insulin solution was prepared by dissolving 10 mg of bovine insulin in 
20 ml of PBS (pH = 7.4).  The crushed polymer microparticles were then dispersed in 
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the insulin solution at 37ºC and stirred at 300 rpm.  After 6 hours, a 0.2ml aliquot was 
removed for loading analysis via syringes equipped with 0.45 µm membrane filters 
and 10 ml of 0.1N HCl was added to the solutions to collapse the polymers, 
effectively entrapping insulin.  The resulting solutions were filtered with cellulose 
acetate/cellulose nitrate filters (0.45 µm, Fisher Scientific, PA).  The polymers were 
further washed with 100 ml 0.1N HCl and 100 ml of de-ionized water.  All glassware 
was siliconized via treatment with Sigmacote® (Sigma). The resulting insulin-loaded 
polymer (ILP) was dried in a lyophilizer (Virts, Gardiner, NY) at –800C and stored at 
–200C.  HPLC was used to determine the insulin content of the wash solutions and the 
resulting insulin content of the ILP was determined via a simple mass balance. 
 As a negative control, Dummy-loaded polymer (DLP) was also prepared.  
These samples were brought through the exact same process as the ILP above except 
the loading solution contained no insulin.  This preparation produced un-loaded 
polymer samples that had been through the same treatments as ILP, incubation and 
network collapse with 0.1N HCl etc., resulting in a control sample that has the same 
surface composition as ILP. 
 
4.2.4 HPLC 
 A Waters Symmetry® 300 column was used with a gradient of 25:75 
acetonitrile/water to 45:55, including 0.1% TFA, over 20 minutes employed as the 
mobile phase.  Samples were injected into a Waters 2690 separations module 
equipped with a 996 Photodiode Array detector at a 1ml/min flow rate 
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4.2.5 Insulin Release 
 To quantify the ability of ILP to release insulin, 10 mg ILP samples were 
dispersed via stirring at 300 rpm in 20 ml PBS in a siliconized vessel at 37ºC.  
Aliquots of 0.2 ml were taken via filter-equipped syringe at set time intervals.  The 
volume was kept constant via immediate replenishment with an equal volume of 
warm PBS.  The insulin concentrations were determined via HPLC.   
 
4.3 Results and Discussion 
 There were essentially three hydrogel synthesis and characterization 
campaigns in this dissertation.  The first campaign produced the hydrogel particles for 
the simulated gastric fluids and Caco-2 cellular transport studies.  Table 4.1 shows the 
results of these efforts.  The remaining 2 synthesis campaigns were for the rodent and 
canine in vivo studies respectively and the results of those efforts are presented in 
Tables 4.2 and 4.3 respectively. 
 As shown in these tables, the average loading percent was approximately 6% 
for all three campaigns and all synthesis were conducted in small batches.  To ensure 
equivalent dosing, an average loading percent was assumed and samples were pooled.   
 
4.4 Conclusions 
 The primary goal of this work was to advance the current methods and 
develop new methods for the in vitro and in vivo characterization of the P(MAA-g-
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EG) hydrogel system.  To this ends, optimal hydrogel preparation methods were 
chosen based on the existing body of knowledge and were not varied throughout this 
research project in order to ensure consistency.  The result is a body of scientific work 
that can be applied to newer hydrogel formulations as they are developed. 
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Table 4.1: ILP Preparations for the Simulated Gastric Fluid Digestions and the 
Caco- 2 Permeability Studies 
 
 
Batch Amount Formulation Loading Insulin Insulin 
  (g) (%) (g) (units) 
A 3.9 5.76 0.23 8390 
B 4.1 4.83 0.19 6932 
C 3.9 5.98 0.23 8390 
D 4.0 6.06 0.24 8756 
F 4.1 6.22 0.26 9485 
    Total: 1.16 41953 
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    Table 4.2: Rodent in vivo Study ILP Synthesis Summary 
 
Insulin Loaded and Dummy Loaded Polymer Sample Summary 
 Amount (mg) Formulation Loading (%)1
Dummy Loaded 
Polymer (DLP) 667.7 0.00 
 
Insulin Loaded 
Polymer Batch 
Identifier (ILP): 
Amount (mg) Formulation Loading (%)1
ILP A1 111.2 4.72 
ILP A2 110.7 4.77 
ILP B1 113.1 5.66 
ILP B2 111.2 5.49 
ILP C1 111.1 5.63 
ILP C2 114.1 5.64 
ILP D1 ≈ 1102 5.29 
ILP D2 ≈ 1102 5.38 
ILP E1 115.8 5.42 
ILP E2 118.6 5.45 
ILP F1 115.3 5.44 
ILP F2 114.2 5.64 
ILP G1 110.6 5.73 
ILP G2 117.9 5.72 
ILP H1 120.0 5.89 
ILP H2 125.6 5.56 
 TOTAL: 1829.4 mg AVG: 5.46 %  
1 – Weight % of insulin in ILP                  2 – Final weight of ILP approximated 
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Table 4.3: Canine in vivo Study ILP Synthesis Summary 
 
Batch Amount Loading Efficiency Formulation Loading Insulin Insulin 
  (g) (%) (%) (g) (units) 
E 3.76 85.6 5.76 0.22 8026 
F 3.95 71.7 4.83 0.20 7067 
G 3.93 89.0 5.98 0.23 8700 
H 3.93 90.5 6.06 0.24 8824 
I 3.91 92.9 6.22 0.24 8990 
      Total: 1.12 41607 
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CHAPTER 5: COMPLEXATION HYDROGELS FOR ORAL PROTEIN 
DELIVERY: AN in vitro ASSESSENT OF THE INSULIN TRANSPORT 
ENHANCING EFFECTS FOLLOWING DISSOLUTION IN SIMULATED 
DIGESTIVE FLUIDS 
 
 
5.1 Introduction 
 
The interest, demand and market potential for advanced drug delivery systems 
for hormones, antibodies and other protein drugs has been well documented 1.  Of 
particular interest is the ability to deliver proteins orally.  Ideally, oral protein 
delivery has the potential to increase patient compliance, lower medical treatment 
costs and provide superior pharmacokinetic profiles 2.  The primary barrier to 
effective oral protein delivery is the ability to obtain adequate bioavailability due to 
drug degradation by proteolytic enzymes and poor transport across epithelial 
membranes as it passes through the gastrointestinal tract. 
One promising approach to oral protein delivery is the use of hydrogel 
technology, which has been studied extensively over the last 2 decades 3-9.  Of 
particular interest are pH-sensitive complexation hydrogels systems, which have 
demonstrated significant promise in oral delivery, especially in the specific 
application of oral insulin delivery 10-13.  The poly(methacrylic acid-g-ethylene 
glycol) (P(MAA-g-EG)) system developed through this work has demonstrated the 
ability to enhance insulin bioavailability in an in situ closed loop model compared to 
insulin alone 12, however the specific mechanism of transport enhancement is 
unknown.  
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In vitro cell culture models are commonly used in the study of drug absorption 
mechanisms 14.  The Caco-2 model, a human intestinal epithelial cell line, is thought 
to satisfy the need for an oral absorption model that predicts in vivo situations in a fast 
and efficient manner 15.  In these models, pure cell lines are grown to confluency on a 
semi-permeable membrane.  Drug or drug formulations are then placed on the apical 
side of the monolayer and transport across the monolayer is determined via 
measurement of drug substance on the basolateral side of culture vessel.  The Caco-2 
model has been used to study the transport of many large molecule drug substances 
including insulin 16-18.  Further, the interest and utility of this model have led to 
significant optimization and study 19-23.  The application of these optimized models 
facilitates a detailed understanding of intestinal drug transport. 
Intestinal absorption of a compound can occur via transcellular passive 
permeability, carrier-mediated transport or paracellular passive permeability 24 or by 
the other routes shown in Figure 2 25.  In general, there are very few hydrophilic 
compounds that can cross the epithelial barrier via the transcellular route, so the 
paracellular or junctional pathway is the only alternative pathway that is available to 
provide adequate drug for systemic bioavailability.   
The specific mechanisms of absorption are of interest in the study of this 
complexation P(MAA-g-EG) hydrogel system as an in vivo model has demonstrated 
higher bioavailability in treatment with insulin-loaded-polymer samples than in the 
case of insulin dosing alone 12.  In these studies, in situ closed loop sections of rat 
intestine were dosed with insulin alone and insulin-loaded polymer (ILP).  The ILP 
samples produced bioavailability of 4.6 – 7.4 % while the bioavailability obtained 
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from insulin alone was significantly less than 1%.  These impressive results drive the 
need to understand exactly how the ILP is enhancing transport.  Transport studies  
using Caco-2 cells and a similar hydrogel system, have quantified some baseline 
insulin permeability values and have generated the hypothesis that the hydrogel 
system may be enhancing insulin transport via the paracellular route 18.   The 
hypothesis surmises that the hydrogels can bind calcium in the cell media and, as 
tight junction integrity is calcium dependent; tight junctions ‘loosen’ allowing the 
drug to pass through.  Experiments designed to measure and monitor tight junction 
integrity using transepithelial electrical resistance measurements (TEER) across 
media of varying calcium concentrations support the Ca2+ dependency of tight 
junction behavior 26,27.  That said, it has long been known that the Caco-2 cell line 
contains the insulin receptor, and, although the specific purpose of the receptor is 
unknown, a possible role of active transport in the insulin transport enhancing effects 
of this hydrogel system cannot be completely dismissed28.     
Lastly, these studies confirmed that the hydrogel systems were not cytotoxic 
to Caco-2 cells, which rules out cellular toxicity damage as a potential mechanism of 
action to explain the bioavailability data but does not rule out irreversible changes to 
tight junction macro and protein structure, which could be interpreted as toxicity-
based mechanisms.  In fact, Ca2+ depletion has been shown to induce significant and 
global changes in cells, which include the disruption of actin filaments and adherent 
junctions as well as diminished cell adhesion some of which have been reported to 
lead to unacceptable side effects 29,30.  As a result, the possibility of a role of active 
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transport and the optimization of receptor mediated epithelial membrane transport 
should not only be seen as possible but also as desirable.   
 In order to further understand and quantify the potential of the P(MAA-g-EG) 
to improve the oral bioavailability of insulin, two questions must be answered more 
thoroughly.   First, a model that demonstrates the ability of this system to protect 
insulin from proteolytic damage in the upper gastrointestinal system is required.  
Initial work on developing this model is underway and recent work has demonstrated 
that this hydrogel system can protect insulin from proteolytic damage in simulated 
gastrointestinal fluids derived from extracts of stomach and intestinal contents from 
Wistar rats 31.  Second, the Caco-2 transport properties must be must be confirmed by 
samples that have passed through these models of gastrointestinal protection and 
extended to include other P(MAA-g-EG) formulations in the hope of confirming the 
proposed mechanisms of cellular transport. 
As a model of gastrointestinal protection and in vivo release, P(MAA-g-EG) 
microparticles were exposed to a sequential series of dissolution studies utilizing 
simulated gastric fluid USP with pepsin (SGF) and simulated intestinal fluid USP 
with pancreatin (SIF).  By the sequential exposure of hydrogel microparticles to SGF 
and SIF prior to the application of these microparticles to the Caco-2 transport model, 
aspects of the prior system characterization are brought together holistically to yield 
the most realistic in vitro model of an oral dose presented to date. 
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5.2 Experimental Section 
5.2.1 Materials 
Methacrylic acid (MAA), pepsin, pancreatin and insulin (bovine and human) 
were purchased from Sigma Aldrich (St. Louis, MO).  Dimethoxy propyl 
acetophenone (DMPA) was purchased from Aldrich (Milwaukee, WI).  The MAA 
was purified via packed column of DE-HIBIT 200 (Polysciences, Warrington, PA) in 
order to remove the inhibitor (hydroquinone monomethyl ether).  Methoxy-
terminated poly(ethylene glycol) monomethacrylate 1000 (PEGMA), and 
tetraethylene glycol dimethacrylate (TEGDMA) were all purchased from 
Polysciences (Warrington, PA).   
 
5.2.2 Hydrogel Synthesis 
 Microparticles of P(MAA-g-EG) were prepared via free-radical solution 
photo-polymerization of MAA and PEGMA 12.  The monomers were mixed in 
appropriate molar ratios to yield a 1:1 ratio of MAA:EG units in the resulting 
hydrogel.  The monomers were then diluted to 44.7% (wt./wt.) of the total monomers 
with a 1:1 (vol./vol.) mixture of ethanol and water.  TEGDMA was added as a cross-
linking agent at X = 0.075 moles TEGDMA per MAA.  DMPA was added as the 
initiator in the amount of 1% weight of the monomers. 
 The reaction mixtures were pipetted into a glass mold that allowed for 
formation of a polymer film with a thickness of 0.8 µm.  The reactions were initiated 
and run to completion by exposing the monomer film to UV light (Ultracure 100, 
Efos, Buffalo, NY) at 1 mW/cm2 at 365 nm for 30 minutes.  The hydrogel films were 
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removed from the molds, rinsed for 1 week in distilled H2O (changed daily) to 
remove the un-reacted monomers and sol fraction. 
 
5.2.3 Insulin loading   
 Hydrogel films were dried under vacuum at 37ºC and then pulverized into fine 
particles using a mill (Bell Art Products, Pequannock, NJ).  The particles were further 
ground using a mortar and pestle and passed through sieves with a particle size cutoff 
of 43 µm.  An insulin solution was prepared by dissolving 10 mg of bovine insulin in 
20 ml of PBS (pH = 7.4).  The crushed polymer microparticles were then dispersed in 
the insulin solution at 37ºC and stirred at 300 rpm.  After 6 hours, a 0.2ml aliquot was 
removed for loading analysis via syringes equipped with 0.45 µm membrane filters 
and 10 ml of 0.1N HCl was added to the solutions to collapse the polymers, 
effectively entrapping insulin.  The resulting solutions were filtered with cellulose 
acetate/cellulose nitrate filters (0.45 µm, Fisher Scientific, PA).  The polymers were 
further washed with 100 ml 0.1N HCl and 100 ml of de-ionized water.  All glassware 
was siliconized via treatment with Sigmacote® (Sigma). The resulting insulin-loaded 
polymer (ILP) was dried in a lyophilizer (Virts, Gardiner, NY) at –800C and stored at 
–200C.  HPLC was used to determine the insulin content of the wash solutions and the 
resulting insulin content of the ILP was determined via a simple mass balance. 
 
5.2.4 HPLC 
 A Waters Symmetry® 300 column was used with a gradient of 25:75 
acetonitrile/water to 45:55, including 0.1% TFA, over 20 minutes employed as the 
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mobile phase.  Samples were injected into a Waters 2690 separations module 
equipped with a 996 Photodiode Array detector at a 1 ml/min flow rate. 
 
5.2.5 Insulin Release 
 To quantify the ability of ILP to release insulin, 10 mg ILP samples were 
dispersed via stirring at 300 rpm in 20 ml PBS in a siliconized vessel at 37ºC.  
Aliquots of 0.2 ml were taken via filter-equipped syringe at set time intervals.  The 
volume was kept constant via immediate replenishment with equal volume of warm 
PBS.  The insulin concentrations were determined via HPLC.  
 
5.2.6 Digestion Studies in Simulated GI Media 
For these studies, simulated intestinal fluid (SIF) and simulated gastric fluid 
(SGF) with enzymes were prepared in accordance with USP standards.  Briefly, SGF 
was prepared by dissolving 2.0 g sodium chloride and 3.2 g purified pepsin derived 
from porcine stomach mucosa (Sigma Aldrich), with an activity of 800-2500 units per 
mg of protein, in 7.0 ml of hydrochloric acid (37%) and sufficient DI water to make 1 
L of solution.  The pH was adjusted to 1.2.   
 To prepare the SIF, 6.8 g of monobasic potassium phosphate (Sigma Aldrich) 
was mixed and dissolved into water.  Sodium hydroxide (Sigma Aldrich, 0.2N) and 
water were added, followed by 10.0 g pancreatin.  The resulting solution was then 
brought to pH 6.8 with 0.2 N NaOH and diluted to a volume of one liter.   
 The SGF digestion was performed by warming 1 liter of SGF to equilibrium 
at 37°C and adding ILP while stirring at 150 rpm.  The ratio of ILP to solution was 
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selected to simulate “sink” conditions.  At time equal to 0, 20, 40, 60 and 120 
minutes, a 0.2 ml aliquot was removed from the dissolution cell via a syringe 
equipped with a 0.45 µm filter.  Fresh SGF (0.2 ml) were back-flushed through the 
filter as media replacement and to return any hydrogel particles adhering to the filter. 
After 2 hours, the entire solution was centrifuged and the supernatant was removed.  
The particles were then washed serially via re-suspension in SGF, followed by 
centrifugation and supernatant removal two times.  After the final collection, half the 
particles were rinsed in pH = 1.2 solution followed by rinsing in HBSS and quickly 
frozen to prevent polymer swelling.  The particles were then lyophilized and stored at 
-20°C. 
 The remaining particles were then subjected to SIF digestion.  These particles 
were placed in 500 ml of SIF and stirred for 6 hours at 150 rpm and 37°C.  Small 
aliquots (0.2 ml) were removed at 0, 30, 45, 60, 120, 240 and 360 minutes.  SIF was 
back-flushed through the filters to maintain constant volume in the dissolution vessels 
and to return particles back into the solutions. After 6 hours, the particles were 
filtered, washed in SIF, centrifuged and recovered as per the SGF digestion.  The 
samples were then washed in PBS (pH=6.8) followed by HBSS, lyophilized and 
stored at -20°C.  
 
5.2.7   Caco-2 Cell Monolayer Transport Studies   
Caco-2 cells were obtained from American Type Culture Collection 
(Rockville, MD).  Caco-2 cells were grown in 75 cm2 Corning flasks in Dulbecco’s 
Modified Eagle Medium (1X, cat. #12430) which was enhanced with 10% fetal 
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bovine serum (v/v), 1% non-essential amino acids and 1% Pen Strep in an incubator 
at 37°C and controlled atmosphere of 90% relative humidity and 5% CO2.  Cells were 
sub-cultured via trypsinization once to twice per week at a cut ratio of 1:3 or 1:4 and 
the media was changed at least once between passages.  The cells were observed 
daily via microscope to ensure adequate growth and monitor for contamination. 
Transport studies were performed in Corning, Transwell plates (Corning Life 
Sciences, Acton, MA. catalog #3491), in which the cells had been grown to 
confluency, typically 20-23 days and a TEER value of greater than 350 Ω cm2.  Cell 
monolayers were exposed to insulin alone (I), insulin in the presence of polymer (PI), 
polymer, which had been previously ‘loaded’ with insulin (ILP), and polymer alone 
as a negative control for insulin.  In addition, ILP samples from the digestion studies 
were also applied. All cells used for these samples came from passages between 88 
and 98. 
 Transepithelial electrical resistance measurements (TEER) were used as a 
measure of tight junction integrity and were performed using the EVOM Epithelial 
Volt-ohmmeter and STX2 Electrode systems from World Precision Instruments.  The 
instrument was used as per manufacturer’s instructions and the electrodes were 
sterilized prior to use and rinsed frequently with diluted ethanol and cell medium to 
prevent cross-contamination. 
 In the TEER studies involving the P, I, PI and ILP samples, the growth media 
was removed from the cells which were then rinsed with Hank’s Balanced Salt 
Solution (HBSS, Invitrogen cat# 24020117).  An initial TEER reading was obtained 
after a 30-60 minute incubation in HBSS.  The media in the apical chamber was then 
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replaced with Insulin solution or 10 mg of P, PI or ILP was added to the existing 
HBSS in the apical chamber.  TEER values were measured at 0, 0.5, 1, 1.5, 2 and 2.5-
hour intervals.  In addition, 100-200 µl samples of apical and basolateral media were 
taken at each time point for insulin concentration determination. The medium in the 
apical and basolateral chambers were then removed and replaced with growth media 
and TEER was monitored further at 4, 8, 12 and 24 hours post-drugging.  Samples of 
medium for insulin concentration determination were also taken at these times.  For 
every four wells that were dosed, one well was used as a negative control and carried 
through the process with cells exposed only to pure HBSS and growth media 
respectively.   
To further assess tight junction behavior, studies were also executed to 
determine the Ca2+ dependency of TEER.  In this case, cells were either exposed to 
HBSS containing full calcium, 1.2 mM, or HBSS with minimum calcium, 0.2 mM 
instead of insulin or insulin/polymer samples.  The data time scale and data collection 
procedure were analogous to the above. 
 
5.2.8 Insulin ELISA EIA 
 Insulin concentration in the medium was determined using ELISA.  Bovine 
Insulin EIA kits (Part # 008-10-1131-01) and Insulin Control Standards (Part # 008-
1135-01) were obtained from ALPCO LTD, Windham, NH.  Media/HBSS samples 
were prepared for assay via serial dilutions of 1:10, 1:100 and/or 1:1000.  Typically, 
apical media samples were diluted 1:100 and 1:1000 and basolateral samples were 
diluted 1:10 and 1:100 based upon the expected concentration differences across the 
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cell monolayer in order to ensure the determined values fell well within the standard 
curve of the assay.  These dilutions were carried out in 96-well plates on a Caliper 
Rapidplate 96/384 Workstation liquid handler (Caliper Life Sciences, Hopkinton, MA 
01748), which also provided extensive mixing cycles between liquid movement steps.  
The cells were diluted with HBSS or cell media depending upon sample type.   
Once the correct dilutions were obtained, an 80-well transfer was performed 
onto the ALPCO EIA plate.  The remaining 16 wells were filled with insulin control 
standards of varying concentrations and known insulin ‘hi/lo’ controls, which were 
used in the post-assay data processing to establish a standard concentration curve.  
The assay was performed via manufacturer protocol and the plates were read on a 
Perkin Elmer Envision plate reader (Perkin Elmer, Downer’s Grove, IL 06484). 
 
5.3 Results and Discussion  
5.3.1 Synthesis, characterization and insulin loading of hydrogel 
 Prior studies in our lab have documented several key parameters of this 
system. The optimum particle diameter for transport has been determined to be ~ 40 
µm and that particle size was used 12.  The pre-digested ILP were found to be 6.4% 
insulin by weight via loading and release study utilizing HPLC.  As 10 mg samples 
were used for dosing, the maximum possible initial insulin load would be 450 µg/ml. 
 
5.3.2 Transepithelial electrical resistance and tight junction monitoring 
 In an effort to characterize the specific mechanism of insulin transport as 
transcellular (across cells) or paracellular (between cells via tight junctions), the 
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transepithelial electrical resistance model (TEER) of tight junction integrity was 
employed.  Figure 5.1 shows the changes in TEER over time for the varying un-
digested sample types.  The negative control (C), I and ILP samples show negligible 
TEER changes over time whereas the P and PI samples demonstrate slightly higher 
TEER variations.  All TEER values returned to normal within 24 hours of dosing.  
Similarly, there are only negligible TEER changes observed in the cases of SGF and 
SIF samples, as shown in Figure 5.2.     
5.3.3 Insulin transport  
 The possible routes of drug transport across cells are depicted schematically in 
Figure 2.2 as adapted from Smith 25.  In order to qualify and quantify insulin 
transport, it is necessary to understand the initial concentration of the media in the 
apical chamber.  Four apical starting conditions were studied and are shown in Figure 
5.5.  In the case of insulin only, an insulin solution was prepared in HBSS to a final 
concentration of 200 µg/ml.  This is the initial insulin concentration (Cia) for the ‘I’ 
and ‘PI’ samples.  The PI samples also contained 10 mg of ‘un-loaded’ hydrogel 
particles suspended in an insulin solution of the same concentration, 200 µg/ml.  The 
initial apical media insulin concentration of the ILP, SGF and SIF samples (Cia) was 
zero, although insulin release began immediately upon contact of these sample types 
and the apical chamber media.  At t=0, all samples were added to the apical chamber.  
In the case of ILP, SGF and SIF, 10 mg of particles were added to the apical chamber 
medium.  In the case of I and PI, the apical medium was removed and replaced with 
insulin solution (I) and insulin solution plus 10 mg of unloaded polymer particles 
(PI).  Insulin transport was quantified and is expressed as concentration profiles of the 
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apical and basolateral chambers in Figures 5.3 and 5.4 respectively.  It should be 
noted that the apical concentrations presented in Figure 5.3 cover time points 
beginning at 4 hours, as the concentrations prior to that were known initial values.  In 
the insulin samples, the concentration of the apical chamber remained relatively 
constant over time, during the 2.5 hour dosing, at ~ 200 µg/ml and the insulin 
transport across the cells was minimal.  The apical concentrations decreased as 
expected after drug removal from 200 µg/ml to ~25 µg/ml, as shown in Figure 13, 
reaching final basolateral concentrations of 100 ng/ml or less, as shown in Figure 14.  
In the case of insulin + polymer, the initial apical concentration dropped quickly from 
~200 µg/ml to ~100 µg/ml during the dosing and stayed essentially constant in the 
apical chamber after dosing at ~100 µg/ml and reached final basolateral 
concentrations of ~100 ng/ml.  In the case of insulin-loaded-polymer (ILP) and ILP 
digested in simulated gastric fluid with pepsin (SGF), the apical concentrations rose 
rapidly from zero to ~300 ng/ml during dosing and remained higher than the insulin 
alone and the polymer + insulin samples at ~300 ng/ml.  This is likely due to the 
incomplete removal of all polymer particles in the apical chamber when drug was 
removed due to adhesion of the ILP to the cell monolayer.  In the cases of these ILP 
and SGF samples, peak basolateral concentrations of 800 ng/ml and 600 ng/ ml 
respectively were reached at 8 hours post dosing.  Finally, in the case of samples 
subjected to digestion in simulated intestinal fluid with pancreatin (SIF), the apical 
and basolateral insulin concentrations never rose above 50 ng/ml ± 10 ng/ml, apical 
data not shown.  The differences in concentration profiles between the sample types 
can be explained by the schematics of Figures 5.5-5.8.  Figure 5.6, demonstrates the 
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high and constant insulin concentration in the apical chamber.  As very little insulin is 
transported across the cell monolayer, the apical insulin concentration remains 
essentially constant.  In Figure 5.7, the same insulin solution is loaded in the presence 
of unloaded polymer and a significant decrease in apical insulin concentration is 
observed while there is little insulin transport across the cell monolayer.  This is 
assumed to be due to uptake of insulin by the hydrogel system as expected at the pH 
of the apical media chamber.  Figure 5.8 demonstrates the mass transfer model of the 
ILP, SGF and SIF samples.  In the case of ILP and SGF, the initial insulin 
concentration in the apical chamber is low but steadily increase as the hydrogel 
matrix relaxes and releases insulin.   
There is also significant insulin transfer across the cell monolayer.  In the case 
of SIF, low insulin concentrations are observed in both the apical and basolateral 
chambers.  This can be explained by the expected release of insulin from the loaded 
polymer samples during the SIF digestion, which is performed at near neutral pH.  As 
there is little insulin left in the polymer post-SIF digestion, the release studies confirm 
low levels of insulin transport.  Figure 5.4 demonstrates the concentration changes in 
the basolateral chamber.  In the case of insulin only and polymer + insulin, the 
maximum concentrations of 100 ± 20 ng/ml were obtained after 4 hours.  In the cases 
of ILP and SGF, the maximum basolateral insulin concentrations of 700 ng/ml ± 100 
ng/ml were obtained approximately 8 hours after dosing.  Finally, the SIF samples 
demonstrated negligible insulin transport with the basolateral concentrations never 
exceeding 50 ng/ml.  The results of the transport study are consistent with earlier 
work in a closed loop intestinal in vivo model 12.  This study demonstrated 
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bioavailability of 4.6%-7.4% from ILP dosing, whereas insulin alone provided 
significantly less than 1% bioavailability.  In the current work, the ILP samples and 
SGF samples demonstrated  
significantly higher insulin transport in the Caco-2 model than did insulin alone at a 
similar ratio of, approximately, 7:1 (700 ng/ml ± 100 ng/ml for ILP and SGF versus 
100 ± 20 ng/ml for insulin alone and polymer + insulin).  Lastly, it should be noted 
that the release profiles of the ILP, SGF and SIF samples provided further evidence of 
the ability of this complexation hydrogel system to both ‘protect’ insulin through the 
low pH and enzymatic environment of the stomach and also to subsequently release 
biologically active insulin into the small intestine under the appropriate physiological 
conditions.   
 
5.3.4 Permeability Quantitation 
 As an accurate comparison of the observed transport phenomena must include 
all aspects discussed above and drug permeability calculations (Papp) are the most 
commonly accepted overall measure.  Table 5.1 shows the permeability coefficients 
for all sample types as calculated using the specific form of Fick’s first law proposed 
by Youdim et al to enable mass balances (Eqn. 1), 32. 
 
 Papp (cm/s) = VD / (A MD) x (∆MR / ∆t)   (Eqn. 1) 
 
Here VD = the apical (donor) volume (cm3), MD = apical (donor) amount (mol), ∆MR 
/ ∆t = change in amount of compound in the basolateral (receiver) chamber over time, 
and A = the membrane surface area (cm2).  The permeability coefficients for each 
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sample type further highlight the differences in insulin transport between the sample 
types.  The permeabilities for SGF and SIF are significantly greater than those for  
insulin and insulin in the presence of polymer, ~110-fold to ~180-fold.  Lastly, as 
expected, the permeability for ILP digested in SIF is the lowest and is only a rough 
estimate as the apical and basolateral insulin concentrations were barely detectable. 
 
5.3.5  Discussion 
 Earlier work has suggested that the insulin transport enhancing effects of this 
hydrogel system may be due to the ability of the system to bind free calcium, which 
can open tight junctions and facilitate insulin transport via the paracellular route 18.  
In this study, the ILP and SGF sample types show the lowest variations in TEER but 
the highest amounts of insulin transfer.  Assuming that TEER is an adequate 
quantitative measure of tight junction integrity, high insulin transfer rates in the 
absence of tight junction ‘loosening’ would suggest a transcellular or active transport 
mechanism.  If this were the primary vehicle of insulin transport, significantly higher 
transport values would be expected in the case of the highest concentration gradient, 
the insulin only samples, but this is not observed.  Similarly, the highest TEER 
fluctuations are seen in the case of PI samples, where the lowest transport is observed.  
The higher TEER fluctuations for these samples can be readily attributed to the 
surface chemistry of the PI samples.  As the insulin loading process involves treating 
the insulin-saturated particles with 0.1 N HCl; to collapse the hydrogel network, polar 
surface groups on the gel surfaces are neutralized by the H+ ions in this step.  As the 
PI samples are never exposed to the acid treatment, the unreacted polar groups result 
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in microparticles that are slightly charged as detected by the TEER measurements.  
Lastly, it has been previously shown that this system is not cytotoxic, so cell death 
and/or damage may be ruled out as possible routes of insulin transport 18.  In light of 
these results, it is probable that the mechanism is mixed, i.e. elements of paracellular 
and transcellular transport are involved.  As previously discussed, the Caco-2 cells do 
contain the insulin receptor so active transport cannot be ruled out.  In addition, other 
factors may contribute such as polymer particle contact time and/or entrapment of the 
ILP polymer particles on and between the cell surfaces.  In the case of ILP and or 
SGF where the most transport was observed, it may simply be that the loaded 
polymer seats itself nicely on the cells and provides a light and steady flow of insulin 
to the cell surfaces for transport.  In the case of PI dosing, the unloaded polymer may 
be incorporating insulin into its matrix while simultaneously lowering the contact 
between insulin and the cells as the polymer may act as a barrier.  In the case of 
insulin only, there may be inadequate contact of the insulin solution due to mucosa or 
other debris on the cell’s surfaces, which can effectively ‘block’ the insulin receptors 
of the Caco-2 cells.   
 
5.4  Conclusions 
 The ability of the novel poly[methacrylic acid-grafted-poly(ethylene glycol)] 
[P(MAA-g-EG)] hydrogel system to protect insulin through gastric conditions was 
confirmed via a dissolution study in simulated gastric fluid with pepsin.  Similarly, 
the ability of this system to release active insulin was demonstrated via dissolution 
studies in simulated intestinal fluid with pancreatin.  The previously demonstrated in 
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vivo capability of this system to enhance insulin transport was confirmed in vitro 
using a Caco-2 cell model of intestinal absorption to study hydrogel samples that had 
been sequentially digested in simulated gastric and intestinal fluids containing 
proteolytic enzymes.  The insulin loaded polymer (ILP) system, and the ILP subjected 
to digestion in simulated gastric fluid with pepsin, demonstrated permeability 
coefficients that were approximately 100 times greater than those of insulin alone.  
ILP, which had been subjected to digestion in simulated gastric fluid, demonstrated a 
minor increase in insulin transport analogous to that of undigested ILP.  
Transepithelial electrical resistance (TEER) studies were utilized to monitor tight 
junction integrity.  As the highest rates of insulin transport did not correlate with the 
greatest variations in TEER, it is concluded that transport is most likely not due to the 
paracellular mechanism alone.  Future pre-clinical in vivo and in silico studies will be 
carried out to determine the required effective dosing for insulin delivery using this 
system, the pharmacokinetics of the system and to determine the elimination 
properties. 
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Table 5.1:  Comparison of Permeability Coefficients (cm/s) and TEER Changes  
 (% of initial value) in Insulin, Insulin + Polymer, Insulin-loaded Polymer  
 (ILP), ILP Digested with SGF and ILP Digested with SGF and SIF.   
Sample Type Permeability 
(cm/s) 
(Papp x 108) 
Maximum TEER Change
(% of initial value) 
Insulin 0.07 less than 10% 
Polymer+Insulin 0.06 30 ± 10% 
Insulin-loaded polymer (ILP) 12.7 16 ± 10% 
SGF-digested ILP 6.61 less than 10% 
SGF and SIF digested ILP 0.01 less than 10% 
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Figure 5.1:  Transepithelial electrical resistance trends during insulin transport 
for the negative control (untreated, C), polymer only (P), insulin only (I), insulin 
in presence of polymer (PI), insulin-loaded polymer (ILP) 
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Figure 5.2:  Transepithelial electrical resistance trends during insulin transport 
for insulin-loaded polymer (ILP), ILP digested in simulated gastric fluid with 
pepsin (SGF) and SGF samples subjected to digestion in simulated intestinal 
fluid (USP) with pancreatin (SIF) 
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Figure 5.3: Apical chamber insulin concentration for insulin only (I), insulin in 
presence of polymer (PI), insulin-loaded polymer (ILP) 
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Figure 5.4:  Basolateral chamber insulin concentration for insulin only (I), 
insulin in presence of polymer (PI), insulin-loaded polymer (ILP), ILP digested 
in simulated gastric fluid with pepsin (SGF) and SGF samples subjected to 
digestion in simulated intestinal fluid (USP) with pancreatin (SIF). 
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Figure 5.5:  Schematic of Experimental Apparatus and Description of Apical 
Starting Conditions.  Cia and Cfa are the Initial and Final Concentrations in the 
Apical Chamber and Cib and Cfb are the Initial and Final Concentrations in the 
Basolateral Chamber. (a) Insulin-only; (b) Polymer in Insulin Solution; (c) 
Insulin-loaded-polymer (ILP) and ILP subjected to Simulated Gastric Fluid with 
Pepsin; (d) ILP Subjected to Simulated Gastric Fluid with Pepsin and Simulated 
Intestinal Fluid with Pancreatin 
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Figure 5.6: Schematic of Insulin Transport and Tight Junction Monitoring of 
Caco-2 Monolayers in the case of Insulin (I) Dosing 
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Figure 5.7: Schematic of Insulin Transport and Tight Junction Monitoring of  
Caco-2 Monolayers in the case of Polymer + Insulin (PI) Dosing 
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Figure 5.8: Schematic of Insulin Transport and Tight Junction Monitoring of 
Caco-2 Monolayers in the case of Insulin-loaded Polymer (ILP) Dosing 
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CHAPTER 6: PHARMACOKINETICS AND PHARMACODYNAMICS OF 
NOVEL COMPLEXATION HYDROGELS FOR ORAL INSULIN DELIVERY 
IN RATS AND DOGS 
 
 
6.1 Introduction 
 
According to the Center for Disease Control, diabetes has become the fastest 
growing disease in the world.  The consensus of the American Diabetes Association 
is that intensive insulin therapy associated with comprehensive self-management 
training should become the standard therapy in patients after puberty 1.  It is this 
comprehensive self-management requirement that brings the highest risk and burden.  
While there are four classes of oral anti-diabetic agents available for Type II diabetes, 
the standard of treatment for Type I is the subcutaneous injection of synthetic human 
insulin.  Oral delivery of protein therapeutics, such as insulin, has the potential to 
increase patient compliance, lower medical treatment costs and provide superior 
pharmacokinetic profiles 2 but these benefits have not yet been realized in insulin 
therapy 3,4. 
 In order to obtain adequate oral bioavailability of protein therapeutics, the 
protein must be protected from degradation from proteolytic enzymes as it passes 
through the upper gastrointestinal tract.  Towards this goal, hydrogel technologies 
have been studied extensively 5-11 and a pH-responsive poly(methacrylic acid-g-
ethylene glycol) system (P(MAA-g-EG)) has been developed and studied for the 
specific goal of oral insulin delivery.12-15.  Previous studies of this system have 
demonstrated the ability of this system to protect insulin through simulated gastric 
conditions 16,17 and to enhance insulin bioavailability in a closed loop in vivo model  
14. 
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 Prior in vivo study of the P(MAA-g-EG) system demonstrated insulin 
bioavailability in in situ closed loop experiments on Sprague Dawley rats that 
exceeded treatment with insulin alone 14.  In these studies, closed sections of rat 
intestine were cleansed and dosed with insulin alone and with insulin-loaded polymer 
samples (ILP).  The ILP samples produced relative systemic bioavailability values of 
4.6 – 7.4% while that obtained from insulin alone was significantly less than 1%.  
While the specific mechanism by which this system enhances transport is unknown, a 
mixed mechanism that combines paracellular and transcellular transport is suspected 
based upon in vitro studies using Caco-2 cells 16.  Further, a relative bioavailability of 
9.5% to subcutaneous insulin was claimed in a recent study of this hydrogel system in 
type 1 and type 2 diabetic rats 18. 
 As all in vivo testing to date has resulted in determination of relative 
bioavailabilities, the aim of the present study is to determine the absolute oral 
bioavailability of insulin delivered via the P(MAA-g-EG) system in  in vivo models 
that more closely mimic the intended clinical application of such a system.   
Pharmacokinetic and pharmacodynamic studies were performed in rats and dogs 
using iv/oral crossover studies.   
Rats were dosed with human insulin intravenously at 1U/kg.  At four-day 
intervals, the same animals were dosed with insulin via gavage with ILP at an oral 
dose of 50 IU/kg.  The iv dose was selected based upon the clinical standard of 1 
U/kg.    Blood serum was collected for human insulin monitoring using an EIA assay 
that was specific for human insulin with minimal cross-activity with rat insulin.  
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The canine studies were conducted utilizing a modified glucose and insulin 
clamping technique as originally described by deFronzo et al 19.  Briefly, this 
technique involves the intravenous administration of basal levels of insulin and 
glucose to hold the blood glucose of the subject at a specified desired value as 
determined by frequent blood sampling.  The test article is then administered and the 
glucose infusion rate is modified as needed to retain the targeted blood glucose value 
for a specified length of time.  Although laborious, this technique offers many 
benefits including greatly increased safety against hypoglycemia and real time data 
and sample collection for detailed pharmacodynamic (glucose and insulin infusion 
rates, blood glucose, c-peptide) and pharmacokinetic (serum insulin) analysis. 
 
6.2 Experimental Section 
 
6.2.1 Animals 
 
All studies were performed in compliance with the Organization for Economic 
Cooperation and Development principles of Good Laboratory Practice. 
Nine female Sprague-Dawley rats (200 – 250 g) were obtained from Charles 
Rivers Laboratory, Portage, Michigan USA.  The animals were maintained as per 
Centocor R&D Vivarium policy.  Cage cards labeled with animal number, test article 
and IACUC protocol number (P-2005-462) and study number were affixed to the 
cages. 
Four random mixed breed female dogs, each weighing approximately 18 kg, 
were obtained the Thomas Jefferson College of Medicine Vivarium.  The dogs were 
kept in separate cages and fed Hills Science Diet dry and canned foods. Cage cards 
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labeled with animal number, test article and IACUC protocol number and study 
number were affixed to the cages. 
 
6.2.2 Materials.    
For the rat studies, methacrylic acid (MAA) and insulin (human) were 
purchased from Sigma Aldrich (St. Louis, MO).  Dimethoxy propyl acetophenone 
(DMPA) was purchased from Aldrich (Milwaukee, WI).  The MAA was purified via 
packed column of DE-HIBIT 200 (Polysciences, Warrington, PA) in order to remove 
the inhibitor (hydroquinone monomethyl ether).  Methoxy-terminated poly(ethylene 
glycol) monomethacrylate 1000 (PEGMA), and tetraethylene glycol dimethacrylate 
(TEGDMA) were all purchased from Polysciences, Warrington, PA.   
For the canine studies, Novolin R, regular human insulin, was obtained from 
Novo Nordisk.  Normal saline (0.9% NaCl in H20) iv bags, 1 liter and 100ml, were 
obtained from Baxter Healthcare, Deerfield IL.  One-liter Dextrose solution (20%) iv 
bags were obtained from Hospira Lake Forest, IL.   
 
6.2.3 Polymer Preparation  
The polymer preparation was consistent across both species.  Microparticles 
of P(MAA-g-EG) were prepared via free-radical solution photo-polymerization of 
MAA and PEGMA 14.  The monomers were mixed in appropriate molar ratios to 
yield a 1:1 ratio of MAA:EG units in the resulting hydrogel.  The solution was then 
diluted to 44.7% (wt./wt.) of the total monomers with a 1:1 (vol./vol.) mixture of 
ethanol and water.  TEGDMA was added as a cross-linking agent at X = 0.075 moles 
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TEGDMA per MAA.  DMPA was added as the initiator in the amount of 1% weight 
of the monomers.  The reaction mixture was pipetted into a mold made of 2 glass 
plates held apart by 0.8mm spacers, creating a polymer film.  The reaction was 
initiated by exposing the monomer film to UV light (Ultracure 100, Efos, Buffalo, 
NY) at 1 mW/cm2 at 365 nm for 30 minutes.  The hydrogel films were removed from 
the molds, rinsed for 1 week in distilled H2O (changed daily) to remove the un-
reacted monomers and sol fraction. 
 
6.2.4 Insulin Loading  
Hydrogel films were completely dried under vacuum at 37 0C.  The dried 
films were then pulverized into fine particles using a mill (Bell Art Products, 
Pequannock, NJ).  The particles were further ground using a mortar and pestle and 
then passed through sieves with a mesh size of 43 µm.  Insulin loading was achieved 
by dissolving 10 mg of human insulin in 20 ml of PBS (pH = 7.4).  The crushed 
polymer microparticles were dispersed in the insulin solution at 37 0C and stirred at 
300 rpm.  After 6 hours, a 0.2ml aliquot was removed via syringes equipped with 
0.45 µm membrane filters and 10 ml of 0.1N HCl was added to the solutions to 
collapse the polymers.  The resulting solutions were filtered with cellulose 
acetate/cellulose nitrate filters (0.45 µm, Fisher Scientific, PA).  The polymers were 
further washed with 100 ml 0.1N HCl and 100 ml of de-ionized water.  All glassware 
was siliconized via treatment with Sigmacote® (Sigma). The resulting insulin-loaded 
polymer (ILP) was dried in a lyophilizer (Virts, Gardiner, NY) at –800C and stored at 
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–200C.  HPLC was used to determine the insulin content of the wash solutions and the 
resulting insulin content of the ILP was determined via a simple mass balance. 
 The above procedure was repeated to produce the negative control sample 
‘dummy-loaded-polymer’, DLP.  For these samples the above procedure was used 
except the microparticles were dispersed in a solution of PBS, instead of human 
insulin.  Al other steps were consistent with those above to ensure comparability. 
 
6.2.5 Insulin Release  
To quantify the ability of ILP to release insulin, 10 mg ILP samples were 
dispersed via stirring at 300 rpm in 20 ml PBS in a siliconized vessel at 37 0C.  
Aliquots of 0.2 ml were taken via filter-equipped syringe at set time intervals.  The 
volume was kept constant via immediate replenishment with equal volume of warm 
PBS.  The insulin concentrations were determined via HPLC. 
 
6.2.6 HPLC  
A Waters Symmetry® 300 column was used with a gradient of 25:75 
acetonitrile/water to 45:55, including 0.1% TFA, over 20 minutes employed as the 
mobile phase.  Samples were injected into a Waters 2690 separations module 
equipped with a 996 Photodiode Array detector at a 1ml/min flow rate. 
 
6.2.7 Rat IV Crossover Study.   
On day 0, the study animals (n=3/ group) were assigned to 1 of 3 treatment 
groups, Control, Insulin and ILP.  The animals in Group 1 received an iv injection of 
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0.25 ml of PBS.  The animals in Groups 2 and 3 received an iv injection of 0.25 ml of 
human insulin (1 U/ml).  All animals were bled at 0, 15, 30, 45 60, 120 and 240 
minutes post dosing for blood glucose and insulin EIA samples.  The blood sample 
were collected via retro orbital sinus under CO2 anesthesia, target volume 250 
µl/bleed into 0.7 ml BD Microtainer serum separation tubes. 
 On Day 3, all animals were orally dosed.  The Control animals received 1.0 
ml of DLP (0 mg/kg insulin).  The ILP animals received 1.0 ml ILP solution (50 
IU/kg insulin) and the Insulin animals received 0.25 ml Insulin solution (1.0 U/ml).  
Blood samples were collected at 1, 2, 3 and 4 hours for human insulin EIA and blood 
glucose measurements.  On day 7, the procedure was repeated exactly except the ILP 
dose was doubled to 100 IU/kg HI and the total volumes of the ILP and DLP doses 
were 2.0 ml.  On day 10, the procedure was executed again as per day 7 except the 
ILP dose was escalated to 200 IU/kg HI.  On days 7 and 10, blood samples were 
collected at 1, 2, 3 and 4 hours as per the day 3 protocol.  The animals were fasted 
overnight only prior to each treatment and were allowed water ad libitum throughout 
the experiments. 
 
6.2.8 Human Insulin Measurement.   
The blood samples were allowed to clot at room temperature for 30 minutes in 
the separation tubes.  Serum was obtained from the clotted samples via centrifugation 
at 2000 – 3000 g for 15 minutes at 40 C.   The human insulin measurements were 
performed using the Linco Human Insulin ELISA kits (Linco Research, St. Charles, 
Mo 63304) Cat.# EZHI-14K, as prescribed by the manufacturer.  This kit uses a 
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sandwich ELISA principle and is capable of specifically detecting 2 to 200 µU/ml 
human insulin from a 20 µl sample while any rat insulin is not detectable at 
concentrations below 120 nM.  No dilutions were required in the rat study and all 
assays yielded results that were well within the quality tolerances of the 
manufacturer. 
6.2.9 Blood Glucose Measurements   
 Blood glucose measurements were obtained using a OneTouch Ultra blood 
glucose meter and OneTouch Ultra glucose test strips (LifeScan Inc.). 
 
6.2.10 Data Processing and Analysis  
All samples were tested in duplicate in the ELISA plates.  The absorbance 
values were measured at 450 nm using a Perkin Elmer Envision plate reader (Perkin 
Elmer, Downer’s Grove, IL 06484).  The dose response curve was constructed using 
the 4-parameter logistic equation functionality of GraphPad PRISM software, version 
4.0 (GraphPad Software Inc.).   
 
 
6.2.11 Canine IV Crossover Study.   
 
Due to the laborious nature of the glucose clamping technique, only one 
animal can be treated per day and each treatment consists of only one dose.  After 
being fasted overnight, the subject dog was transported from the Vivarium to the 
treatment suite.  Intravenous catheters were inserted into each foreleg using 22 gauge 
BD Insyte Autoguard shielded iv catheters.  The dog was placed in a padded bed on 
heating pads set at a gentle level and one person was on the floor with the dog at all 
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times to monitor for stress and offer comfort.  At time t=0, an initial blood glucose 
measurement was taken and the dog was connected to an iv infusion of 20% dextrose 
solution.  Once the blood glucose reached 100 mg/dl, an iv infusion of insulin 
solution, 1IU/ml, was initiated.  The initial infusion rates were set based upon 
literature values, primarily from veterinary literature and human glucose clamping 
protocols20-22.  The infusions were accomplished using Alaris® IVAC Signature Gold 
Infusion pumps (Cardinal Health, Dublin, Ohio 43017) and the corresponding 
disposable iv cassettes and tubing sets.  Blood sampling occurred every 5 minutes and 
the glucose infusion rate was titrated to ensure that the blood glucose remained steady 
at 100 mg/dl.  Once the blood glucose remained between 90 and 110 mg/dl for more 
than 30 minutes, the clamp was established and a dose of test article could be given.   
The test articles included a ‘no sample’ study, which was simply a control 
experiment of the clamping technique in each dog, an iv insulin bolus of between 0.1 
and 0.2 IU/kg, oral ILP doses of 50 – 100 IU/kg, and an oral insulin solution of 0.1 – 
0.2 IU/kg.  The clamp was maintained and monitored for four hours post-dosing for 
all sample types.  During his time, blood glucose measurements were taken every 5 
minutes and serum samples were collected every 10 minutes for insulin and c-peptide 
quantification.  In order to ensure the safety of the animal immediately after the 
procedure, the animal was slowly released from the clamp during the last of the four-
hour experiment as follows.  The insulin infusion was stopped at t = 3 hours and 15 
minutes post-dosing.  The glucose infusion was terminated fifteen minutes later and 
the dog was fed and allowed to roam the treatment room.  After 30 more minutes of 
sample collection and feeding, the dog was returned to her run.  Each dog was 
 163
accessed a total of 4 times for treatment with at least 7 days rest between each 
treatment.  After protocol completion, the dogs were successfully placed in loving 
homes. 
 
6.2.12 Analytics   
The blood glucose and human insulin analysis and data processing were 
conducted exactly as they were for the rat study using the Linco Human Insulin EIA, 
OneTouch blood glucose meter and the GraphPad Prism software respectively. 
 The canine c-peptide concentrations were determined using the Linco Canine 
C-Peptide RIA kits (CCP-24HK, Linco Research, St. Charles, Missouri 63304) as per 
the manufacturers instructions.  The standard curve and data processing was 
accomplished using GraphPad Prism as per the EIA experiments above. 
 
 
6.3 Results 
 
 The resulting dose response curve in the rat study from the iv dose is shown in 
Figure 6.1.   The 2-hour and 4-hour time points have been removed to aid 
visualization of numeric integration of the iv curves shown in Figure 6.1 and the oral 
dose response curves, and the oral dose response curves, data not shown, over the 
entire 4-hour sampling time.  The absolute bioavailability of insulin delivered from 
the hydrogel system was then determined as per Equation 1 23.   The area under the 
curve (AUC) values were determined by the method of least squares and utilized to 
determine bioavailability as shown in equation 6.1 below 
Bioavailability (F) = 
po
iv
iv
po
Dose
Dose
AUC
AUC ×     (6.1) 
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It was determined that the mean absolute bioavailability in rats of insulin delivered 
from this hydrogel system was approximately 1% ± 60%.    The wide variation is due 
to significant differences in the results obtained from the 3 rats in the oral ILP group, 
which had individual bioavailability values of 0.2%, 0.1% and 2.5% respectively. 
 The canine study yielded similar results.  Figure 6.2 demonstrates the basal 
insulin and glucose levels during a glucose clamp control experiment where no test 
article was given.  After an initial blood glucose measurement at t=0, the animal was 
placed on an infusion of 20% dextrose until a blood glucose level of 100 mg/dl was 
obtained, which occurred at approximately t = 10 min.  At that time, an infusion of 
human insulin is initiated at a steady rate (IIR).  The glucose infusion rate (GIR) was 
varied to ‘clamp’ the blood glucose at 100 mg/dl.  After ~3.0 hours, the insulin 
infusion was discontinued followed by the cessation of the glucose infusion.  The 
animal was fed and its blood glucose is monitored for an additional 30 minutes to 
ensure safety.  Figure 6.2 shows that the mean blood glucose level was successfully 
maintained at ~100 mg/dl and the basal serum insulin concentration was ~10 mU/l 
following the initial iv insulin bolus.   
 The details of a glucose clamp experiment containing an oral ILP dose is 
presented in Figure 6.3.  This chart chronicles the entire 5-hour experiment.  The 
initial upswing in the glucose infusion rates correlates with the administration of iv 
glucose followed by the iv insulin infusion.  By 50 minutes, the blood glucose and 
glucose infusion rates have stabilized and basal insulin level has balanced at 20 mU/l 
and the oral ILP dose is administered.     
 
 165
Approximately 50 minutes later, the pharmacodynamic effect is most pronounced as 
demonstrated by the sharp increase in glucose infusion required to maintain the 
glucose clamp at 100 mg/dl.  While the spike in serum insulin concentration lasts for 
just a few half-lives, the resulting pharmacodynamic effect last more than 80 minutes 
as evidenced by the duration of time the glucose infusion rates must be maintained 
above the basal values of 20-30 ml/hr.   The insulin dose response curves for the iv 
and oral ILP doses for all four dogs are shown in Figures 6.4 and 6.5 respectively.  As 
per the rat study, the curves were shifted so that the exact time of dosing, usually 60-
90 minutes after initiation of the glucose clamp, was set equal to zero and integrated 
over a four-hour period to determine the AUC for each animal from each dose.  The 
resulting mean absolute bioavailability was 0.002 ± 11%. 
 The pharmacodynamic response to the ILP doses is presented in Figure 6.6.  
The clear and significant blood glucose lowering effects of the ILP doses are evident 
by study of the glucose infusion rates.  In the case of ‘Tawny’, it is theorized that one 
of the two ILP capsules did not leave the stomach until much later in the experiment, 
resulting in the second glucose infusion rate peak.  When normalized back to the time 
of dosing, the peak pharmodynamic effect occurs between 50 and 90 minutes post 
oral dose. 
 In an attempt to model the fate of insulin delivered from the ILP system, the 
following correlations were applied 24: 
Foral = (1-fG)(1-fH)(1-fabs)    (Eqn. 2) 
fG = 1 – AUCpo/AUChpv    (Eqn. 3) 
fH = 1 – AUChpv/AUCiv    (Eqn. 4) 
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where fabs, fG, and fH represent the fraction of insulin lost in the gastrointestinal tract, 
at the gut wall and in the liver respectively.  It is important to note that these 
equations are based on hepatic portal vein cannulation and AUChpv cannot be 
experimentally determined otherwise.  The detailed pharmacokinetic results for both 
species are presented in Table 6.1. To ensure animal safety and to minimize 
morbidity, literature values for AUChpv were obtained and utilized 25.  The results of 
the application of the above model are presented in Table 6.2.  As evidenced from the 
consistently high fG values, this model suggests that the majority of insulin is lost at 
the gut wall.  Lastly, it is clear from this data that the absolute oral bioavailability in 
rats and dogs is extremely similar if the single instance of F > 1% is eliminated from 
consideration.   
 
6.4 Discussion 
 
Prior work on the oral insulin delivery capability of P(MAA-g-EG) hydrogels 
has reported bioavailability values that are significantly higher than those produced 
by this study.  As previously discussed, Nakamura et al reported relative 
bioavailability amounts of 4.6% - 7.2% in in situ closed loop studies in rats 14.     
Interesting results are obtained when the when the bioavailability model above is 
applied.  In simulating the closed loop model, fabs can be assumed to be zero as the 
ILP is placed directly into the loop of intestine and fH can be assumed to be 0.5 from 
the literature. When the mean relative bioavailability from this study, 5.9%, is 
inserted into the model, the resulting value for the fraction of insulin lost at the gut 
wall (fG) is 0.882.    As the experimental procedure included fasting the rats for 24 
hours and the rinsing of the isolated illeal segment with a significant volume of 
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phosphate buffered saline (PBS), it is fair to assume that the difference in 
bioavailability between the current work and the in situ work lies in the treatment of 
the gut wall which results in a significantly lowered fG, from 0.981 to 0.882 
respectively.    Specifically, in a fasted state, the enzymatic composition and action of 
the intestinal segment is expected to be greatly reduced 26.  Further, the PBS wash 
most likely decreased or altered the enzymatic composition of the glycocalix as 
closed loop studies, by the same authors, have demonstrated that PBS rinsing can 
lower enzymatic activity in rats 27.  This effect has been confirmed in unpublished 
work in our lab.  That said, it is clear that the gut wall is the controlling resistance in 
both studies.  Similarly, the variance in results between the current work and the 
recently published rat in vivo work can be explained.   Morishita et al report a 
maximum relative bioavailability of 9.5% in their recent work but also report that the 
hypoglycemic effects of the ILP system decrease with shortening the fasted period 18.  
As the rats in that study were fasted for 48 hours prior to the study and the rats in the 
current work were fasted overnight only, it is fair to surmise that some of the 
difference in experimental outcomes are due to the differences in fasting times.  This 
hypothesis is further supported by basic physiology of the small intestine as it is well 
known that motility patterns of the small intestine are profoundly altered by eating 
and that gastric and intestinal secretions are greatly induced by feeding 28.  Based on 
these core concepts as well as the correlation of values obtained by the study of two 
species, the authors feel that the current work offers the most physiologically relevant 
model, presented to date, of the bioavailability of insulin delivered from this novel 
complexation hydrogel system. 
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 As the low absolute bioavailability values reflect significant insulin loss, the 
authors have applied well-established kinetic models to determine the most likely 
points of loss as shown in Figure 6.6.  It is clear that the loss at the gut wall (fG) is 
most significant in all cases but the loss in the gastrointestinal tract appears to vary 
significantly.  This most likely due to the nature of mass transport and mixing in the 
lumen of the gastrointestinal system, which is often mathematically characterized via 
the principle of random walks 29.  The 1st-pass hepatic effect can be seen as negligible 
as it appears that most insulin has been lost prior to reaching the hepatic portal vein. 
 
6.5 Conclusions 
 With respect to future work, this study provides clear insight and direction.  
First, it is clear that affecting insulin absorption at the gut wall can make the largest 
gains in oral bioavailability.  Improving the mucoadhesive properties of the polymer 
system to prolong contact time with the gut wall as well as use of 
penetration/absorption enhancers may all offer benefits.  Further, the current work 
demonstrates that the system does protect the protein from proteolytic damage in the 
upper gastrointestinal tract by design and that losses in the lumen of the small 
intestine are of smaller consequence.  Lastly, as it is clear that the protein is arriving 
in the small intestine intact and is quickly released at the corresponding pH levels, it 
may make sense to consider the utilization of this system to deliver protein and 
peptide therapeutics that are intended to have regional effect versus systemic.  One 
example would be the delivery of antibody or other protein therapies to the intestinal 
tract to treat local disorders such as Crohn’s disease. 
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Table 6.1: Absolute Bioavailability and Pharmacokinetic Parameters of Insulin 
Delivered via ILP 
 
Dog Doseiv Dosepo AUCiv AUCpo FOral
Freckles 0.15 50 7605 3504 0.0014 
Breezy 0.1 50 6321 6871 0.0018 
Elvis 0.2 50 4369 7939 0.0022 
Tawny 0.15 50 9333 4265 0.0014 
Mean : 0.15 50 6907 5645 0.0017 
Stdev: 0.040825 0 2094 2102 0.0004 
Rat Doseiv Dosepo AUCiv AUCpo FOral
Rat 1 1 50 7656 786.4 0.002 
Rat 2 1 50 14246 750.7 0.0011 
Rat 3 1 50 13450 17079 0.0254 
Mean:  1 50 11784 6205 0.0095 
Stdev: 0 0 3597 9417 0.014 
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Table 6.2:  Pharmacokinetic Parameters from Model of Insulin Loss 
 
Dog Fh Fg Fabs FOral
Freckles 0.42 0.998 0.0001 0.0014 
Breezy 0.42 0.996 0.172 0.0018 
Elvis 0.42 0.987 0.697 0.0022 
Tawny 0.42 0.998 0.0001 0.0014 
Mean : 0.42 0.994 0.290 0.002 
Stdev: 0 0.006 0.371 0.0004 
Rat Fh Fg Fabs FOral
Rat 1 0.5 0.998 0.0001 0.0014 
Rat 2 0.5 0.998 0.999 0.0011 
Rat 3 0.5 0.949 0.999 0.0254 
Mean:  0.5 0.981 0.991 0.01 
Stdev: 0 0.028 0.015 0.014 
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Figure 6.1:  Human Insulin iv Dose Response Curve in Sprague-Dawley Rats 
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Figure 6.2: Euglycemic insulinemic clamp with no sample administered.  ¡   
Blood Glucose,  Glucose Infusion Rate, ▲Insulin Infusion Rate,  Serum 
Insulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 173
Freckles ILP Dose Response (50 IU/kg)
0
20
40
60
80
100
120
140
160
0 50 100 150 200 250 300
Time (minutes)
B
lo
od
 G
lu
co
se
 (m
g/
dl
), 
In
fu
si
on
 R
at
es
 (m
l/h
r)
0
10
20
30
40
50
60
70
80
90
In
su
lin
 (m
U
/L
)
 
Figure 6.3: Details of single ILP administration procedure. ¡ Blood Glucose,  
 Glucose Infusion Rate, ▲Insulin Infusion Rate,  Serum Insulin 
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Figure 6.4: Human Insulin IV Dose Response ¡ ‘Breezy’ 0.1 U/kg,  ‘Freckles’ 
0.15 U/kg, ▲ ‘Elvis 0.2 U/kg and  Tawny 0.15 U/kg 
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Figure 6.5: Human Insulin ILP Dose Response ¡ ‘Freckles’,  ‘Breezy’ ▲ 
‘Elvis  Tawny 
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Figure 6.6:  ILP Pharmacodynamic Dose Response ¡ ‘Freckles’,  ‘Breezy’  
▲‘Elvis,  Tawny 
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Figure 6.7:  Sites of insulin loss in the gastrointestinal system.  Most insulin is 
lost at the gut wall where fG = 0.994. 
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CHAPTER 7:  INSULIN SATURABILITY. A CASE REPORT OF A MASSIVE 
INTRAVENOUS INSULIN OVERDOSE IN A HEALTHY DOG 
 
 
7.1 Introduction 
 
 The current theory on insulin saturation assumes that there are two potential 
sites; the first site involves transporting the insulin across the endothelium, from the 
plasma to the interstitial fluid.  The second site involves insulin binding to its 
receptors on insulin-sensitive cells and its downstream effects.  In the current study, 
due to an administration error, an 18 kg dog received 180 units of insulin iv (10 
IU/kg) instead of 1.8 IU total (0.1 IU/kg).  The mistake was immediately realized and, 
due to the inherent safety-centric design of the euglycemic-hyperinsulinemic 
clamping approach, the dog successfully recovered after more than 10 total hours of 
treatment.  During this time, blood glucose was measured every 5 minutes and serum 
was collected for serum insulin and c-peptide measurements every 10 minutes.  The 
resulting data provide a truly unique view of insulin absorption, metabolism and 
elimination of intravenous insulin. 
 
 
7.2  Experimental Section 
 
The original study design included the use of euglycemic insulinemic 
clamping in order to assess the absolute bioavailability of insulin delivered orally via 
a pH sensitive complexation hydrogel delivery system.  Four random mixed-breed 
female dogs, each weighing approximately 18 kg, were obtained from the Thomas 
Jefferson University College of Medicine Vivarium for the study.  After 4-5 days of 
acclimation in the vivarium, the dogs were to be accessed weekly for a single dose 
 182
response study for a total of 4-6 total treatments over 4-6 weeks.  The study utilized a 
crossover design with a baseline clamp performed week 1, an iv insulin dose week 2, 
an oral insulin loaded polymer (ILP) dose week three and an oral insulin solution 
dose on week four.  Weeks five and six were reserved for repeat dosing for any 
problem experiments and/or additional ILP administration at different doses. 
 
7.2.1 Glucose Clamping Technique 
A euglycemic-hyperinsulinemic clamp was established based upon the 
methods of DeFronzo et al 1.  Briefly, the dog was fasted overnight and allowed water 
ad libitum.  Intravenous catheters were inserted into each foreleg, one to be used for 
sample extraction and the other for intravenous administration.  After an obtaining an 
initial, t=0, blood sample of approximately 0.6 mls, iv infusion of glucose was 
initiated at a rate of 133 mg/min dextrose.  Blood glucose (bg) samples were drawn at 
5- minute intervals and monitored using a OneTouch Ultra© meter until the blood 
glucose exceeded 100 mg/dl.  Once this level was obtained, an insulin infusion was 
initiated at a rate of 0.4 IU/hr.  The glucose infusion rate (GIR) was adjusted to 
maintain a steady-state blood glucose level of 100 mg/dl ± 10mg/dl.  All intravenous 
infusions were administered and controlled using Alaris IVAC IV infusion pumps.  
Once this level held for 30 minutes, the dog was considered ‘clamped’ and the test 
article, in this case an iv insulin bolus was administered. 
By accident, instead of 1.8 IU/kg insulin, a total dose of 180 IU was 
administered iv, a 100X overdose.  The error was recognized immediately and the 
glucose infusion was aggressively increased and the insulin infusion was 
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discontinued.  Blood chemistry values were measured using a commercial blood 
chemistry analyzer and a potassium infusion was added to bring the blood potassium 
values back to within normal parameters.  The clamp was maintained until the dog 
was fed and capable of maintaining blood glucose of greater than 70 mg/dl without 
supplemental glucose.  This was approximately 9 hours after the administration of the 
insulin bolus.  The following day, blood chemistry was measured twice and serum 
samples were collected for insulin concentration determination. 
 
7.2.2 Analytics 
The all blood samples for serum insulin and c-peptide measurements were 
allowed to clot for 45 minutes at room temp in BD Microtainer Serum Separation 
Tubes.  The samples were spun at 5g for 5 minutes.  The serum was collected into 
clean 1.5 ml Eppendorf centrifuge tubes and stored at –200C until assay.  The serum 
insulin concentrations were determined using the Linco commercial ELISA EIA kit 
(EZHI-14K), Linco Research, St. Charles, Missouri. 
 
7.3 Results and Discussion 
Due to aggressive management of the glucose clamp, the blood glucose never 
dropped below 50 mg/dl and never exceeded 300 mg/dl.  Figure 7.1 presents the 
blood glucose, glucose infusion rates and blood insulin levels of the dog throughout 
the procedure.  The peak insulin value exceeded 30 IU/liter briefly shortly after the 
insulin bolus.  The serum insulin concentration remained above 10 IU/liter for more 
than 75 minutes and was higher than 1 IU/liter for more than three hours.  During this 
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time, the dog displayed minor discomfort, yawning/gagging, as well as periods of 
tachycardia and shallow respirations.  Mostly, the dog slept.  The basal blood glucose 
concentration of the clamp was initially raised to greater than 250 mg/dl to prevent 
the blood sugar from plummeting and was gradually and painstakingly reduced over 
time to the pre-dose levels of approximately 75 mg/dl.  The dog stood to stretch and 
urinate approximately every 90 minutes and showed interest in food approximately 7 
hours post-dose.  Once the dog was fed and appeared bright, alert and reactive, he 
was returned to her pen overnight.  The dog recovered fully and returned to the 
protocol.  Figure 7.2 shows the procedure repeated one week later with an oral 
insulin-loaded hydrogel dose.  The dog showed normal and expected responses and a 
tight clamp was maintained.  Table 7.1 shows the detailed blood chemistries obtained 
during the procedure.  As the potassium levels were very low during the procedure, 
intravenous potassium was administered to maintain critical electrolyte balance. 
 
7.4 Conclusions 
The blood glucose and insulin levels that were drawn during the management 
of the insulin overdose, help explain the two sites of insulin saturability.  The fact that 
the serum insulin concentration remained above 10 IU/liter for more than 75 minutes 
and was higher than 1 IU/liter for more than three hours, supports the view that there  
is a saturable process that transports the insulin from the plasma to the interstitial 
fluid.2  Dernovsek found that insulin was not degraded by endothelial cells, but rather, 
it was able to pass through the cells.3  Later, King showed that endothelial cells are 
able to transport insulin across them, most likely by a specific receptor-mediated 
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process.4  A study looking at insulin concentrations in both the plasma and lymph 
fluid, found that the transport of insulin across the endothelial cells was mostly due to 
diffusion, and that an insignificant receptor-mediated component may also exist.5  
However, in our model, the insulin levels may have become so un-physiologic that 
the insignificant receptor-mediated component became significant, and the diffusion 
pathway may have been saturated.  Dernovsek postulated that the endothelial cells 
could be used as a storage area for insulin, but our data can neither support nor 
counter this theory.3
 The amount of glucose that needed to be infused to maintain adequate blood 
glucose, even after the plasma insulin declined, supports the idea that there is a 
second site of insulin saturation.2 This site of insulin saturability is less controversial, 
as much is known about the insulin receptor and its downstream effects.  60-80% of 
the insulin is taken up by the liver, 10-20% by the kidneys, and the remaining insulin 
is taken up by the skeletal muscle and adipose tissue.  It has been thought that 
lymphocytes and adipose tissue may act as storage areas for insulin, since it was 
found that they both release non-degraded insulin.6,7  Whether this mechanism played 
a role when the interstitial fluid was flooded with insulin is unknown. 
 The high levels of insulin in the plasma for an extended period of time, and 
the high levels of glucose that needed to be infused, even after the plasma insulin 
levels declined, support a two receptor site saturability. 
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Table 7.1: Canine Blood Chemsitry Values from 10 IU/kg Dose 
Time (min) BG (mg/dl) GIIR (ml/min) K+ IR BUN HcT Na+ K+
190 186 280 14 7 24 137 2 
240 156 225 14 7 21 135 2 
310 141 185 16 7 26 139 2.2 
405 160 140 16 6 25 139 2.9 
470 147 97.5 16 5 26 141 3.5 
515 106 47.5 12 5 29 142 3.7 
545 102 47.5 10 4 26 148 3.3 
585 78 30 10 4 25 142 3.3 
640 70 0 0 4 30 145 3.1 
1590 95 0 0 9 45 146 4.2 
1820 100 0 0 15 47 145 4 
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Figure 7.1: Blood Glucose and Serum Insulin during 10 IU/kg Dose 
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Figure 7.2: Oral Hydrogel Dose Response 1 week later on same dog as 
 received the 10 IU/kg Dose 
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CHAPTER 8:  CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE 
WORK 
 
8.1 Conclusions 
 
 The overall goal of this work was to provide the most detailed and realistic in 
vitro and in vivo analysis on the P(MAA-g-EG) hydrogel system to date and to 
establish a clear path forward for the optimization and, potentially, commercialization 
of this novel oral protein delivery vehicle.  During this evaluation, a single 
formulation of the hydrogel was used consistently throughout the characterization to 
limit the introduction of extraneous variables that could complicate the analysis. 
 Hydrogel preparations consisted of a 1:1 monomer ratio of methacrylic acid to 
ethylene glycol diluted to a solvent fraction of 44.7% (wt./wt.) ethanol and water.  
The resulting hydrogel films were ground down into particles and sieved resulting in 
a maximum particle size of 43 µm.  The polymer was loaded with insulin to an 
average of 6% of total weight of the resulting ILP.  The ILP batches were prepared 
for three campaigns; the cell work, the rat study and the canine study and the average 
insulin loading percentage from each batch was used for the entire campaign.  
 During the cell work, the insulin transport capability of the system was 
confirmed using the Caco-2 cell line.  The ability of the hydrogel system to protect 
entrapped insulin from the chemical and biochemical hazards of the upper 
gastrointestinal tract was confirmed via dissolution studies in simulated gastric fluids 
containing active pepsin.  Further the pH-responsive behavior of this system was 
confirmed via a serial dissolution study in simulated gastric and simulated intestinal 
fluids each containing active enzymes.  The enhanced permeability of insulin in the 
Caco-2 cell live relative to insulin alone was confirmed via transport studies using 
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semi-permeable membranes.  The correlation between cell permeability and 
transepithelial electrical resistance (TEER) was determined and it was found that the 
maximum cell permeability did not always correspond with the largest variations in 
TEER, suggesting that paracellular transport may not be the sole mechanism of 
transport enhancement of the polymer system. 
 The in vivo characterization of the system began with an iv-crossover-to-oral 
study in Sprague-Dawley rats.  The absolute bioavailability in rats was determined for 
a single ILP dose, 50 IU/kg.  The bioavailability obtained in this study was 
significantly less than that reported in prior rodent in vivo studies 1.   As the rodent 
model has significant limitations for absolute bioavailability studies such as limited 
blood sampling, risk, difficulty and complications of delivering the ILP via gavage or 
gelcap etc., the system was evaluated in a canine model.  Hyperinsulinemic 
euglycemic insulin clamping was employed as a basis of an analogous iv-crossover 
study in healthy female dogs.  The resulting absolute bioavailabilies determined were 
essentially equal to those found in the rat model. 
 Lastly, as the bioavailability values obtained in these in vivo studies were 
significantly lower than expected, pharmacokinetic models were employed to 
determine the nature and location of the drug loss.  A hepatic cannulation model 
based upon the assumptions that drug metabolism/loss occurs in a series fashion 
based upon the site of administration suggests that most of the insulin is 
metabolized/lost at the gut wall. 
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8.2 Recommendations 
 The results of this work offer a clear path forward for optimizing this 
promising oral protein delivery system.  If transport across the intestinal mucosa and 
gut wall can be improved, even by as little as 20%, there will be significant increases 
in oral biovailaibility.  For example, a 15% reduction in resistance at the gut wall can 
yield a six-fold increase in bioavailability as demonstrated in Figure 6.6.  Further, as 
the ability of the system to protect entrapped proteins through the upper 
gastrointestinal tract and to release the cargo in the small intestine have been 
confirmed, this system could be very valuable as a vehicle to deliver drugs locally to 
the intestinal mucosa.  The remainder of this chapter will propose several paths 
forward. 
 
8.2.1 Optimization of Mucoadhesion 
In the consideration of improving uptake of protein across the gut wall, two 
aspects should be considered; the creation and maintenance of a maximum 
concentration of drug on the apical surface of the mucosa as well as optimizing 
transport across the mucosa.  As applied to the current work, the ILP will very 
quickly deliver the payload once it reaches an area of adequately elevated pH.  Once 
released, the protein is mixed, and effectively diluted, with the chyme and other 
contents of the intestinal lumen.  It would be ideal if the release could be more 
specific and localized.  To this end, there is already ongoing work on mucoadhesion.  
This is not a new concept and, in fact, optimization of the mucoadhesive properties of 
this hydrogel system date back a decade and the current formulation is the result of 
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significant work on that front 2.   That said, there remains room for improvement.  An 
ideal situation would be the case where the polymer particles attached well to the 
intestinal mucosa and drug release was one-directional towards the gut wall.  This 
would eliminate or greatly reduce the amount of drug lost in dilution in the intestinal 
contents and/or destroyed by proteolytic enzymes of the small intestine.  He et al 
reports the development of one such device in the recent literature 3.   This group has 
developed a self-folding miniature device comprised of a finger-like bilayer structure 
made up of pH-sensitive hydrogel layer and a non-swelling layer based on 
poly(hydroxyethyl methacrylate) (PHEMA).  A mucoadhesive drug layer is attached 
on the bilayer and the authors propose that this self-folding device first attaches to the 
mucous and then curls into the mucous based upon the different swelling in the 
bilayer.  It is also proposed that the PHEMA layer can serve as a diffusive barrier to 
prevent drug leakage into the intestine.  This mico device concept has also been 
explored in approaches such as intestinal patches.  An intestinal patch system for the 
delivery of erythropoetin (EPO) has recently been reported and has shown some 
capability to enhance EPO transport in the presence of absorption enhancers in in situ 
rat studies4.   
 
8.2.2 Optimization of epithelial transport 
Once adequate and sustained contact with the epithelial membrane has been 
achieved, the ability of the delivered drug to cross the gut wall must be enhanced.  
This is truly a case of man versus nature as the gut wall is specifically designed and 
regulated to prevent the passage of pathogens and toxins, many of which are proteins.  
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As a mixed mechanism of insulin absorption cannot be ruled out based on the work to 
date, both paracellular and transcellular mechanisms could possibly exploited.  It has 
been theorized that the system has the ability to loosen tight junctions via the uptake 
of calcium ions and that this mechanism may play a key role in the increased insulin 
bioavailability seen in early in situ studies5, 6.  This may be true but this mechanism 
must be approached utilized carefully as previous work using calcium chelators have 
led to unacceptable side effects 7.  A more optimal route would be to consider 
exploiting the zonulin system.  The zonula occludens toxin (ZOT) is known to play a 
significant role in the modulation of tight junctions 8.  Alternatively, mechanisms to 
enhance and promote active transport across the epithelial cells by insulin receptors 
should and are being considered.  Lastly, while there is significant effort and promise 
in these approaches, a far deeper understanding of cell biology is required and a 
collaboration that brings deep cell biology expertise onboard with the current 
program should be seriously considered. 
 
8.2.3 Application of P(MAA-g-EG) system to other drugs 
Another opportunity for increasing the utility is to consider applying the 
system for targeted versus systemic therapies.  By modifying the polymer to enable 
the delivery of other protein therapeutics, especially drugs targeting the 
gastrointestinal tract, the potential for commercialization may be greatly enhanced.  
One example would be to deliver antibody directly therapies to the intestinal mucosa 
for applications such as Crohn’s disease.  Not only would this approach play to the 
current strengths of the P(MAA-g-EG) system, it would greatly reduce the need for 
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the drug to be systemically available, and, therefore, reduce the need to transport 
active protein and peptide therapeutics across the intestinal mucosa.
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